8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 21, 2017

HealthSouth Corporation

(Exact name of Registrant as specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-10315	63-0860407
(Commission File Number)	(IRS Employer Identification No.)

3660 Grandview Parkway, Suite 200, Birmingham, Alabama 35243

(Address of Principal Executive Offices, Including Zip Code)

(205) 967-7116

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

The information contained herein is being furnished pursuant to Item 2.02 of Form 8‑K, “Results of Operations and Financial Condition,” and Item 7.01 of Form 8-K, “Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 2.02. Results of Operations and Financial Condition.

On February 21, 2017, HealthSouth Corporation (the “Company”) issued a press release reporting the financial results of the Company for the three months and year ended December 31, 2016. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on hospitals open throughout both the full current and prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.

ITEM 7.01. Regulation FD Disclosure.

See Item 2.02, “Results of Operations and Financial Condition,” above.

In addition, a copy of the supplemental information which will be discussed during the Company’s earnings call at 9:00 a.m. Eastern Time on Wednesday,February 22, 2017 is attached to this report as Exhibit 99.2 and incorporated herein by reference.

During tomorrow’s earnings call, Mr. Mark Tarr, President and Chief Executive Officer of the Company, will provide the following observations: “We are pleased with the rebound in volumes we have experienced within both segments since the second half of January and believe our volumes for the first quarter of 2017 will be in line with our expectations. As a reminder, we estimate the inpatient rehabilitation hospitals’ discharge growth in the first quarter of 2016 benefited by approximately 80 to 100 basis points due to the extra day associated with leap year.”

This information shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Note Regarding Presentation of Non-GAAP Financial Measures

The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow.

The Company is providing adjusted earnings per share from continuing operations attributable to HealthSouth (“adjusted earnings per share”). The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing performance to prior periods given that it excludes the impact of government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operations. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company’s ongoing operations. Accordingly, they can complicate comparisons of the Company’s results of operations across periods and comparisons of the Company’s results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States (“GAAP”) as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. The Company reconciles adjusted earnings per share to earnings per share in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.

The leverage ratio referenced therein is defined as the ratio of consolidated total debt to Adjusted EBITDA for the trailing four quarters. The Company believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its

debt and its ability to make capital expenditures. Additionally, the leverage ratio is a standard measurement used by investors to gauge the creditworthiness of an institution. The Company’s credit agreement also includes a maximum leverage ratio financial covenant which allows the Company to deduct up to $75 million of cash on hand from consolidated total debt. The Company reconciles Adjusted EBITDA to net income and to net cash provided by operating activities in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. Adjusted EBITDA for the Company’s reportable segments is reconciled to net income from continuing operations before income tax expense in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.

The Company uses Adjusted EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Liquidity and Capital Resources,” and Note 9, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10‑K for the year ended December 31, 2016 (the “2016 Form 10‑K”), when filed. These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under the credit agreement—its interest coverage ratio and its leverage ratio—could result in the Company’s lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might be on terms less favorable to those in the Company’s existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the Company’s assessment of its liquidity.

In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as “Adjusted Consolidated EBITDA,” allows the Company to add back to consolidated net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated net income (1) all unusual or nonrecurring items reducing consolidated net income (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations and closed locations, (3) costs and expenses, including legal fees and expert witness fees, incurred with respect to litigation associated with stockholder derivative litigation, and (4) share-based compensation expense. The Company also subtracts from consolidated net income all unusual or nonrecurring items to the extent they increase consolidated net income.

The calculation of Adjusted EBITDA under the credit agreement does not require us to deduct net income attributable to noncontrolling interests or gains on disposal of assets and development activities. It also does not allow us to add back professional fees unrelated to the stockholder derivative litigation, losses on disposal of assets, unusual or nonrecurring cash expenditures in excess of $10 million, and charges resulting from debt transactions and development activities. These items and amounts, in addition to the items falling within the credit agreement’s “unusual or nonrecurring” classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to our ongoing operations. Accordingly, these items may not be indicative of our ongoing performance, so the Adjusted EBITDA calculation presented here includes adjustments for them.

Adjusted EBITDA is not a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2016 Form 10-K.

The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company’s capacity to reduce debt, pursue development activities, and return capital to its common stockholders. The calculation of adjusted free cash flow and a reconciliation of net cash provided by operating activities to adjusted free cash flow are included in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company’s definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2016 Form 10‑K, when filed, and in the press release attached as Exhibit 99.1 for the GAAP measures of cash flows from operating, investing, and financing activities.

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be non-indicative of its ongoing operations. Such items include government, class action, and related settlements; professional fees-accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operations. These items are uncertain and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP.

Forward-Looking Statements

The information contained in the press release and supplemental information includes certain estimates, projections, and other forward-looking statements that involve known and unknown risks and relate to, among other things, future events, the Company’s business strategy, financial plans, dividend strategies or payments, effective income tax rates, plans to repurchase its debt or equity securities, future financial performance, projected business results or model, ability to return value to its shareholders, projected capital expenditures, leverage ratio, acquisition opportunities, and the impact of future legislation or regulation. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “targets,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These estimates, projections, and other forward-looking statements are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.

There can be no assurance that any estimates, projections, or forward-looking statements will be realized.

All such estimates, projections, and forward-looking statements speak only as of the date hereof. The Company undertakes no duty to publicly update or revise that information.

You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking statements in this report, the press release, and supplemental information as they are based on current expectations and general assumptions and are subject to various risks, uncertainties, and other factors, including those set forth in the attached press release and in the 2016 Form 10‑K, when filed, and in other documents the Company previously filed with the SEC, many of which are beyond the Company’s control. These factors may cause actual results to differ materially from the views, beliefs, and estimates expressed herein.

ITEM 9.01. Financial Statements and Exhibits.

(d)    Exhibits.

Exhibit Number	Description
99.1	Press release of HealthSouth Corporation, dated February 21, 2017.
99.2	Supplemental information provided in connection with the fourth quarter 2016 earnings call of HealthSouth Corporation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTHSOUTH CORPORATION

By:	/S/   DOUGLAS E. COLTHARP
	Name:	Douglas E. Coltharp
	Title:	Executive Vice President and Chief Financial Officer

Dated: February 21, 2017

EX-99.1

Exhibit 99.1

Media Contact	February 21, 2017
Casey Lassiter, 205 641-1118	For Immediate Release
casey.lassiter@healthsouth.com
Investor Relations Contact
Crissy Carlisle, 205 970-5860
crissy.carlisle@healthsouth.com

HealthSouth Reports Strong Revenue and Earnings Growth

for Fourth Quarter 2016 and Reiterates Full-Year 2017 Guidance

BIRMINGHAM, Ala. - HealthSouth Corporation (NYSE: HLS), one of the nation's largest providers of post-acute healthcare services, offering both facility-based and home-based post-acute services, today reported its results of operations for the fourth quarter ended December 31, 2016.

“We are very pleased with the 2016 operating and financial results of our facility-based and home-based business segments,” said Mark Tarr, President and Chief Executive Officer of HealthSouth. “We've been able to successfully execute on our stated objectives for the year of integrating Reliant and CareSouth, adding capacity to both business segments, increasing clinical collaboration between those segments, reducing our financial leverage, and continuing our program of shareholder distributions. With these achievements, we are poised for continued success in 2017.”

Consolidated Results

					Growth
	Q4 2016		Q4 2015		Dollars			Percent
	(In Millions, Except per Share Data)
Net operating revenues	$	949.9	$	879.3	$	70.6		8.0	%
Income from continuing operations attributable to HealthSouth per diluted share	0.68		0.48		0.20			41.7	%
Adjusted earnings per share	0.72		0.59		0.13			22.0	%
Cash flows provided by operating activities	116.0		116.6		(0.6		)	(0.5	)%
Adjusted EBITDA	198.8		191.5		7.3			3.8	%
Adjusted free cash flow	78.3		83.0		(4.7		)	(5.7	)%
	Year Ended December 31,
	2016		2015
Cash flows provided by operating activities	605.5		484.8		120.7			24.9	%
Adjusted free cash flow	462.9		389.0		73.9			19.0	%

Revenue growth was driven primarily by pricing growth in the inpatient rehabilitation segment and volume growth in the home health and hospice segment.

The increase in income from continuing operations attributable to HealthSouth per diluted share and adjusted earnings per share primarily resulted from increased Adjusted EBITDA. Both earnings per share amounts also included the impact of a lower effective tax rate year over year, lower interest expense resulting from the redemptions of the Company's 7.75% Senior Notes due 2022 in the first nine months of 2016, and a lower share count resulting from share repurchases. The Company benefited from a lower state tax rate driven by the Reliant and CareSouth acquisitions.

1

Exhibit 99.1

Cash flows provided by operating activities were relatively flat for the fourth quarter of 2016 compared to the fourth quarter of 2015. Growth in cash flows provided by operating activities for full-year 2016 primarily resulted from revenue growth.

Revenue growth also was the primary driver of the increase in Adjusted EBITDA.

Adjusted free cash flow decreased in the fourth quarter of 2016 compared to the fourth quarter of 2015 due to increased maintenance capital expenditures, as discussed below, and increased cash payments for taxes due to the exhaustion of the Company's federal net operating loss in December 2016 and the tax impact of the gain on the sale of its pediatric home health assets in November 2016.

Adjusted free cash flow for full-year 2016 grew 19.0% due to increased Adjusted EBITDA and favorable working capital changes. Working capital changes were mainly attributable to the recovery of payments that were delayed for administrative reasons at the Company's largest Medicare Administrative Contractor (“MAC”) and the timing of payroll-related liabilities. Adjusted free cash flow in 2016 also included increased cash interest expense related to the financing of the Reliant and CareSouth acquisitions, increased cash payments for taxes, as discussed above, and increased maintenance capital expenditures. Increased maintenance capital expenditures in 2016 resulted from growth in the Company's inpatient rehabilitation segment, enhancements to the hospital maintenance program, and refurbishments at certain larger hospitals.

See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.

Inpatient Rehabilitation Segment Results

					Growth
	Q4 2016		Q4 2015		Dollars			Percent
Net operating revenues:	(In Millions)
Inpatient	$	740.9	$	696.8	$	44.1		6.3	%
Outpatient and other	26.7		29.1		(2.4		)	(8.2	)%
Total segment revenue	$	767.6	$	725.9	$	41.7		5.7	%
	(Actual Amounts)
Discharges	41,474		40,891		583			1.4	%
Same-store discharge growth								0.1	%
Net patient revenue per discharge	$	17,864	$	17,040	$	824		4.8	%
	(In Millions)
Adjusted EBITDA	$	197.6	$	189.9	$	7.7		4.1	%

• Revenue - Revenue growth resulted primarily from an increase in net patient revenue per discharge and new-store volume growth. Growth in net patient revenue per discharge resulted from patient mix (higher percentage of stroke patients and the integration of the Reliant hospitals). Discharge growth from new stores resulted from the Company's joint ventures in Hot Springs, Arkansas (February 2016), Bryan, Texas (August 2016), and Broken Arrow, Oklahoma (August 2016), as well as the opening of wholly owned hospitals in Franklin, Tennessee (December 2015) and Modesto, California (October 2016).

The decrease in outpatient and other revenues primarily was due to the closure of six outpatient programs in certain markets.

• Adjusted EBITDA - The increase in Adjusted EBITDA for the inpatient rehabilitation segment resulted primarily from revenue growth. Salaries and benefits increased as a percent of net operating revenues due to the ramp up of new stores and staffing increases at the Reliant hospitals since their acquisition on October 1, 2015. Hospital operating expenses as a percent of net operating revenues decreased by 20 basis points year over year as higher self-insurance costs were offset by continued supply chain efficiencies, including the continued transition of brand name drugs to generic. Bad debt expense as a percent of net operating revenues decreased from 1.8% in the fourth quarter of 2015 to 1.7% in the fourth quarter of 2016 due primarily to the recovery of payments that were delayed for administrative reasons at the Company's largest MAC.

2

Home Health and Hospice Segment Results

					Growth
	Q4 2016		Q4 2015		Dollars		Percent
Net operating revenues:	(In Millions)
Home health	$	165.2	$	144.4	$	20.8	14.4	%
Hospice and other	17.1		9.0		8.1		90.0	%
Total segment revenue	$	182.3	$	153.4	$	28.9	18.8	%
	(Actual Amounts)
Admissions	27,957		22,892		5,065		22.1	%
Same-store admissions growth							14.0	%
Episodes	49,253		42,697		6,556		15.4	%
Same-store episode growth							12.4	%
Revenue per episode	$	3,023	$	3,005	$	18	0.6	%
	(In Millions)
Adjusted EBITDA	$	28.0	$	26.5	$	1.5	5.7	%

• Revenue - Revenue growth resulted from strong same-store and new-store volume growth. Growth from new stores resulted primarily from the acquisition of CareSouth (acquired November 2, 2015).

Higher revenue per episode was due to patient mix offset partially by Medicare reimbursement rate cuts. The shift in patient mix was driven by increased clinical collaboration with HealthSouth's inpatient rehabilitation hospitals and the integration of CareSouth.

• Adjusted EBITDA - Growth in Adjusted EBITDA resulted primarily from revenue growth. Adjusted EBITDA for the segment was impacted by higher cost per visit (driven by an increased percentage of therapy patients), salary and benefit cost increases, and expenses related to the integration of CareSouth.

Repurchases of Common Stock

During the fourth quarter of 2016, the Company repurchased 1,054,754 shares of its common stock for $41.5 million in the open market. Throughout 2016, the Company repurchased a total of 1,666,721 shares of its common stock for approximately $64 million. As of December 31, 2016, the Company had a remaining repurchase authorization of approximately $96 million.

Full-Year Consolidated Results

	Full-Year				Growth
	2016		2015		Dollars		Percent
	(In Millions, Except per Share Data)
Net operating revenues	$	3,707.2	$	3,162.9	$	544.3	17.2	%
Income from continuing operations attributable to HealthSouth per diluted share	2.59		1.92		0.67		34.9	%
Adjusted earnings per share	2.67		2.24		0.43		19.2	%
Adjusted EBITDA	793.6		682.5		111.1		16.3	%

Revenue growth primarily resulted from strong volumes in both of the Company's operating segments and included the effect of the Company's acquisitions of Reliant on October 1, 2015 and CareSouth on November 2, 2015.

The increase in income from continuing operations attributable to HealthSouth per diluted share and adjusted earnings per share primarily resulted from increased Adjusted EBITDA. Both earnings per share amounts included the impact of higher depreciation and amortization related to acquisitions and capital investments, higher interest expense related to the financing of

3

the Reliant and CareSouth acquisitions, and a lower share count resulting from share repurchases. See the attached supplemental information for additional details regarding these calculations.

“Our substantial free cash flow generation in 2016 allowed us to further strengthen our balance sheet, reducing our financial leverage, while we continued our shareholder distributions,” said Doug Coltharp, Executive Vice President and Chief Financial Officer of HealthSouth. “In 2017, we will continue to enjoy significant flexibility in how we allocate free cash flow.”

2017 Guidance

In a current report on Form 8-K dated January 9, 2017, the Company provided its initial guidance ranges for 2017. The Company is confirming the following guidance ranges.

Full-Year 2017 Guidance Ranges
(In Millions, Except Per Share Data)
Net operating revenues	$3,850 to $3,950
Adjusted EBITDA	$800 to $820
Adjusted earnings per share from continuing operations attributable to HealthSouth	$2.61 to $2.73

For additional considerations regarding the Company's 2017 guidance ranges, see the supplemental information posted on the Company's website at http://investor.healthsouth.com. See also the “Other Information” section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.

Earnings Conference Call and Webcast

The Company will host an investor conference call at 9:00 a.m. Eastern Time on Wednesday,February 22, 2017 to discuss its results for the fourth quarter of 2016. For reference during the call, the Company will post certain supplemental information at

http://investor.healthsouth.com.

The conference call may be accessed by dialing 877 587-6761 and giving the pass code 53698402. International callers should dial 706 679-1635 and give the same pass code. Please call approximately ten minutes before the start of the call to ensure you are connected.The conference call will also be webcast live and will be available at http://investor.healthsouth.com by clicking on an available link.

An on-line replay of the conference call will be available after the live broadcast at http://investor.healthsouth.com.

About HealthSouth

HealthSouth is one of the nation's largest providers of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. HealthSouth can be found on the Web at www.healthsouth.com.

Other Information

The information in this press release is summarized and should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Form 10-K”), when filed, as well as the Company's Current Report on Form 8-K filed on February 21, 2017 (the “Q4 Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at

http://investor.healthsouth.com for reference during its February 22, 2017 earnings call.

The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q4 Earnings Form 8-K. Readers are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial

4

Measures” included in the Q4 Earnings Form 8-K which provides further explanation and disclosure regarding the Company’s use of these non-GAAP financial measures.

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise non-indicative of its ongoing operations. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP.

However, the following reasonably estimable GAAP measures for 2017 would be included in the reconciliation for Adjusted EBITDA:

• Provision for doubtful accounts - estimate of 1.8% to 2.0% of net operating revenues

• Interest expense and amortization of debt discounts and fees - estimate of $165 million to $175 million

• Amortization of debt-related items - approximately $15 million

The Q4 Earnings Form 8-K and, when filed, the 2016 Form 10-K can be found on the Company's website at

http://investor.healthsouth.com and the SEC's website at www.sec.gov.

5

HealthSouth Corporation and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

	For the Three Months Ended December 31,						For the Year Ended December 31,
	2016			2015			2016			2015
	(In Millions)
Net operating revenues	$	949.9		$	879.3		$	3,707.2		$	3,162.9
Less: Provision for doubtful accounts	(14.5		)	(14.0		)	(61.2		)	(47.2		)
Net operating revenues less provision for doubtful accounts	935.4			865.3			3,646.0			3,115.7
Operating expenses:
Salaries and benefits	516.3			466.8			1,985.9			1,670.8
Other operating expenses	125.1			118.0			492.1			432.1
Occupancy costs	17.8			16.8			71.3			53.9
Supplies	35.8			34.6			140.0			128.7
General and administrative expenses	36.8			36.0			133.4			133.3
Depreciation and amortization	43.8			41.4			172.6			139.7
Government, class action, and related settlements	—			(0.5		)	—			7.5
Professional fees—accounting, tax, and legal	—			0.3			1.9			3.0
Total operating expenses	775.6			713.4			2,997.2			2,569.0
Loss on early extinguishment of debt	—			2.4			7.4			22.4
Interest expense and amortization of debt discounts and fees	41.6			44.6			172.1			142.9
Other income	(0.8		)	(1.3		)	(2.9		)	(5.5		)
Equity in net income of nonconsolidated affiliates	(2.5		)	(2.4		)	(9.8		)	(8.7		)
Income from continuing operations before income tax expense	121.5			108.6			482.0			395.6
Provision for income tax expense	39.7			43.5			163.9			141.9
Income from continuing operations	81.8			65.1			318.1			253.7
Income (loss) from discontinued operations, net of tax	0.3			0.7			—			(0.9		)
Net income	82.1			65.8			318.1			252.8
Less: Net income attributable to noncontrolling interests	(16.8		)	(18.8		)	(70.5		)	(69.7		)
Net income attributable to HealthSouth	65.3			47.0			247.6			183.1
Less: Convertible perpetual preferred stock dividends	—			—			—			(1.6		)
Net income attributable to HealthSouth common shareholders	$	65.3		$	47.0		$	247.6		$	181.5

(Continued) 6

HealthSouth Corporation and Subsidiaries

Condensed Consolidated Statements of Operations (Continued)

(Unaudited)

	For the Three Months Ended December 31,				For the Year Ended December 31,
	2016		2015		2016		2015
	(In Millions, Except Per Share Data)
Weighted average common shares outstanding:
Basic	88.6		90.1		89.1		89.4
Diluted	99.2		100.6		99.5		101.0
Earnings per common share:
Basic earnings per share attributable to HealthSouth common shareholders:
Continuing operations	$	0.73	$	0.51	$	2.77	$	2.03
Discontinued operations	—		0.01		—		(0.01		)
Net income	$	0.73	$	0.52	$	2.77	$	2.02
Diluted earnings per share attributable to HealthSouth common shareholders:
Continuing operations	$	0.68	$	0.48	$	2.59	$	1.92
Discontinued operations	—		0.01		—		(0.01		)
Net income	$	0.68	$	0.49	$	2.59	$	1.91
Cash dividends per common share	$	0.24	$	0.23	$	0.94	$	0.88
Amounts attributable to HealthSouth common shareholders:
Income from continuing operations	$	65.0	$	46.3	$	247.6	$	184.0
Income (loss) from discontinued operations, net of tax	0.3		0.7		—		(0.9		)
Net income attributable to HealthSouth	$	65.3	$	47.0	$	247.6	$	183.1

7

HealthSouth Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

	December 31, 2016		December 31, 2015
	(In Millions)
Assets
Current assets:
Cash and cash equivalents	$	40.5	$	61.6
Restricted cash	60.9		45.9
Accounts receivable, net of allowance for doubtful accounts of $53.9 in 2016; $39.3 in 2015	443.8		410.5
Prepaid expenses and other current assets	109.3		80.7
Total current assets	654.5		598.7
Property and equipment, net	1,391.8		1,310.1
Goodwill	1,927.2		1,890.1
Intangible assets, net	411.3		419.4
Deferred income tax assets	75.8		190.8
Other long-term assets	221.3		197.0
Total assets	$	4,681.9	$	4,606.1
Liabilities and Shareholders’ Equity
Current liabilities:
Current portion of long-term debt	$	37.1	$	36.8
Accounts payable	68.3		61.6
Accrued payroll	147.3		126.2
Accrued interest payable	25.8		29.7
Other current liabilities	197.1		172.1
Total current liabilities	475.6		426.4
Long-term debt, net of current portion	2,979.3		3,134.7
Self-insured risks	110.4		101.6
Other long-term liabilities	49.6		43.0
	3,614.9		3,705.7
Commitments and contingencies
Redeemable noncontrolling interests	138.3		121.1
Shareholders’ equity:
HealthSouth shareholders’ equity	735.9		611.4
Noncontrolling interests	192.8		167.9
Total shareholders’ equity	928.7		779.3
Total liabilities and shareholders’ equity	$	4,681.9	$	4,606.1

8

HealthSouth Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	For the Year Ended December 31,
	2016			2015
	(In Millions)
Cash flows from operating activities:
Net income	$	318.1		$	252.8
Loss from discontinued operations, net of tax	—			0.9
Adjustments to reconcile net income to net cash provided by operating activities—
Provision for doubtful accounts	61.2			47.2
Provision for government, class action, and related settlements	—			7.5
Depreciation and amortization	172.6			139.7
Amortization of debt-related items	13.8			14.3
Loss on early extinguishment of debt	7.4			22.4
Equity in net income of nonconsolidated affiliates	(9.8		)	(8.7		)
Distributions from nonconsolidated affiliates	8.5			7.7
Stock-based compensation	27.4			26.2
Deferred tax expense	132.9			127.1
Other, net	0.1			(0.6		)
Change in assets and liabilities, net of acquisitions—
Accounts receivable	(127.5		)	(134.1		)
Prepaid expenses and other assets	(3.3		)	(9.6		)
Accounts payable	6.3			0.9
Accrued payroll	9.8			(18.1		)
Other liabilities	11.8			13.8
Premium received on bond issuance	—			9.8
Premium paid on redemption of bonds	(5.8		)	(13.7		)
Windfall tax benefits from share-based compensation	(17.3		)	—
Net cash used in operating activities of discontinued operations	(0.7		)	(0.7		)
Total adjustments	287.4			231.1
Net cash provided by operating activities	605.5			484.8

(Continued) 9

HealthSouth Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Continued)

(Unaudited)

	For the Year Ended December 31,
	2016			2015
	(In Millions)
Cash flows from investing activities:
Acquisitions of businesses, net of cash acquired	(48.1		)	(985.1		)
Purchases of property and equipment	(177.7		)	(128.4		)
Additions to capitalized software costs	(25.2		)	(28.1		)
Proceeds from disposal of assets	23.9			4.0
Proceeds from sale of marketable securities	—			12.8
Purchase of restricted investments	(1.3		)	(7.1		)
Net change in restricted cash	(15.1		)	2.7
Other, net	(1.6		)	(1.1		)
Net cash provided by investing activities of discontinued operations	0.1			0.5
Net cash used in investing activities	(245.0		)	(1,129.8		)
Cash flows from financing activities:
Principal borrowing on term loan facilities	—			250.0
Proceeds from bond issuance	—			1,400.0
Principal payments on debt, including pre-payments	(202.1		)	(597.4		)
Borrowings on revolving credit facility	335.0			540.0
Payments on revolving credit facility	(313.0		)	(735.0		)
Principal payments under capital lease obligations	(13.3		)	(11.0		)
Debt amendment and issuance costs	—			(31.9		)
Repurchases of common stock, including fees and expenses	(65.6		)	(45.3		)
Dividends paid on common stock	(83.8		)	(77.2		)
Dividends paid on convertible perpetual preferred stock	—			(3.1		)
Distributions paid to noncontrolling interests of consolidated affiliates	(64.9		)	(54.4		)
Windfall tax benefits from share-based compensation	17.3			—
Other, net	8.8			5.2
Net cash (used in) provided by financing activities	(381.6		)	639.9
(Decrease) increase in cash and cash equivalents	(21.1		)	(5.1		)
Cash and cash equivalents at beginning of period	61.6			66.7
Cash and cash equivalents at end of period	$	40.5		$	61.6
Supplemental schedule of noncash financing activity:
Preferred stock conversion	$	—		$	93.2

10

HealthSouth Corporation and Subsidiaries

Supplemental Information

Earnings Per Share

	QTD							YTD
	Q4 2016			Q4 2015				Q4 2016			Q4 2015
	(In Millions, Except Per Share Data)
Adjusted EBITDA	$	198.8		$	191.5			$	793.6		$	682.5
Interest expense and amortization of debt discounts and fees	(41.6		)	(44.6		)		(172.1		)	(142.9		)
Depreciation and amortization	(43.8		)	(41.4		)		(172.6		)	(139.7		)
Stock-based compensation expense	(10.0		)	(4.4		)		(27.4		)	(26.2		)
Noncash gain (loss) on disposal or impairment of assets	1.3			(2.4		)		(0.7		)	(2.6		)
	104.7			98.7				420.8			371.1
Certain items non-indicative of ongoing operations:
Government, class action, and related settlements	—			0.5				—			(7.5		)
Professional fees—accounting, tax, and legal	—			(0.3		)		(1.9		)	(3.0		)
Loss on early extinguishment of debt	—			(2.4		)		(7.4		)	(22.4		)
Transaction costs	—			(6.7		)		—			(12.3		)
Pre-tax income	104.7			89.8				411.5			325.9
Income tax expense (1)	(39.7		)	(43.5		)	(2)	(163.9		)	(141.9		)	(2)
Income from continuing operations (3)	$	65.0		$	46.3			$	247.6		$	184.0
Basic shares	88.6			90.1				89.1			89.4
Diluted shares	99.2			100.6				99.5			101.0
Basic earnings per share (3)	$	0.73		$	0.51			$	2.77		$	2.03
Diluted earnings per share (3)	$	0.68		$	0.48			$	2.59		$	1.92

⁽¹⁾  Current income tax expense for the three months ended December 31, 2016 and 2015 was $17.4 million and $4.4 million, respectively. Current income tax expense for the year ended December 31, 2016 and 2015 was $31.0 million and $14.8 million, respectively.

⁽²⁾  The Company's effective income tax rate was higher than the statutory rate due to an increase in the Company's valuation allowance related to certain state net operating losses.

⁽³⁾  Income from continuing operations attributable to HealthSouth.

11

HealthSouth Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	Q4					Full Year
	2016			2015		2016			2015
Earnings per share, as reported	$	0.68		$	0.48	$	2.59		$	1.92
Adjustments, net of tax:
Government, class action, and related settlements	—			—		—			0.04
Professional fees — accounting, tax, and legal	—			—		0.01			0.02
Mark-to-market adjustments for stock appreciation rights	0.02			—		0.01			0.01
Income tax valuation allowance and other tax adjustments	(0.01		)	0.05		(0.01		)	0.05
Transaction costs	—			0.05		—			0.08
Loss on early extinguishment of debt	—			0.01		0.04			0.13
Sale of home health pediatric assets and hospital	0.03			—		0.02			—
Adjusted earnings per share*	$	0.72		$	0.59	$	2.67		$	2.24

* Adjusted EPS may not sum due to rounding.

12

HealthSouth Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	For the Three Months Ended December 31, 2016
				Adjustments
	As Reported			Mark-to-Market Adjustment for Stock Appreciation Rights			Sale of Pediatric Home Health Assets and Hospital			Income Tax Valuation and Other Adjustments			As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	198.8		$	—		$	—		$	—		$	198.8
Depreciation and amortization	(43.8		)	—			—			—			(43.8		)
Interest expense and amortization of debt discounts and fees	(41.6		)	—			—			—			(41.6		)
Stock-based compensation	(10.0		)	3.0			—			—			(7.0		)
Loss on disposal or impairment of assets	1.3			—			(3.3		)	—			(2.0		)
Income from continuing operations before income tax expense	104.7			3.0			(3.3		)	—			104.4
Provision for income tax expense	(39.7		)	(1.1		)	6.1			(0.6		)	(35.3		)
Income from continuing operations attributable to HealthSouth	$	65.0		$	1.9		$	2.8		$	(0.6	)	$	69.1
Add: Interest on convertible debt, net of tax	2.5												2.5
Numerator for diluted earnings per share	$	67.5											$	71.6
Diluted earnings per share from continuing operations**	$	0.68		$	0.02		$	0.03		$	(0.01	)	$	0.72
Diluted shares used in calculation	99.2

* Reconciliation to GAAP provided on page 17

** Adjusted EPS may not sum across due to rounding.

13

HealthSouth Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	For the Three Months Ended December 31, 2015
				Adjustments
	As Reported			Gov't, Class Action, & Related Settlements			Prof. Fees - Acct., Tax, & Legal			Income Tax Valuation Allowance & Other Adj.		Transaction Costs			Loss on Early Exting. of Debt			As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	191.5		$	—		$	—		$	—	$	—		$	—		$	191.5
Depreciation and amortization	(41.4		)	—			—			—		—			—			(41.4		)
Government, class action, and related settlements	0.5			(0.5		)	—			—		—			—			—
Professional fees - accounting, tax, and legal	(0.3		)	—			0.3			—		—			—			—
Loss on early extinguishment of debt	(2.4		)	—			—			—		—			2.4			—
Interest expense and amortization of debt discounts and fees	(44.6		)	—			—			—		—			—			(44.6		)
Stock-based compensation	(4.4		)	—			—			—		—			—			(4.4		)
Loss on disposal or impairment of assets	(2.4		)	—			—			—		—			—			(2.4		)
Transaction costs	(6.7		)	—			—			—		6.7			—			—
Income from continuing operations before income tax expense	89.8			(0.5		)	0.3			—		6.7			2.4			98.7
Provision for income tax expense	(43.5		)	0.2			(0.1		)	4.7		(2.1		)	(1.0		)	(41.8		)
Income from continuing operations attributable to HealthSouth	$	46.3		$	(0.3	)	$	0.2		$	4.7	$	4.6		$	1.4		$	56.9
Add: Interest on convertible debt, net of tax	2.4																	2.4
Numerator for diluted earnings per share	$	48.7																$	59.3
Diluted earnings per share from continuing operations**	$	0.48		$	—		$	—		$	0.05	$	0.05		$	0.01		$	0.59
Diluted shares used in calculation	100.6

* Reconciliation to GAAP provided on page 17

** Adjusted EPS may not sum across due to rounding.

14

HealthSouth Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	For the Year Ended December 31, 2016
				Adjustments
	As Reported			Prof. Fees - Acct., Tax, & Legal			Mark-to-Market Adjustment for Stock Appreciation Rights			Loss on Early Exting. of Debt			Sale of Pediatric Home Health Assets and Hospital			Income Tax Valuation and Other Adjustments			As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	793.6		$	—		$	—		$	—		$	—		$	—		$	793.6
Depreciation and amortization	(172.6		)	—			—			—			—			—			(172.6		)
Professional fees - accounting, tax, and legal	(1.9		)	1.9			—			—			—			—			—
Loss on early extinguishment of debt	(7.4		)	—			—			7.4			—			—			—
Interest expense and amortization of debt discounts and fees	(172.1		)	—			—			—			—			—			(172.1		)
Stock-based compensation	(27.4		)	—			1.6			—			—			—			(25.8		)
Loss on disposal or impairment of assets	(0.7		)	—			—			—			(4.2		)	—			(4.9		)
Income from continuing operations before income tax expense	411.5			1.9			1.6			7.4			(4.2		)	—			418.2
Provision for income tax expense	(163.9		)	(0.8		)	(0.6		)	(3.0		)	6.5			(0.6		)	(162.4		)
Income from continuing operations attributable to HealthSouth	$	247.6		$	1.1		$	1.0		$	4.4		$	2.3		$	(0.6	)	$	255.8
Add: Interest on convertible debt, net of tax	9.7																		9.7
Numerator for diluted earnings per share	$	257.3																	$	265.5
Diluted earnings per share from continuing operations**	$	2.59		$	0.01		$	0.01		$	0.04		$	0.02		$	(0.01	)	$	2.67
Diluted shares used in calculation	99.5

* Reconciliation to GAAP provided on page 17

** Adjusted EPS may not sum across due to rounding.

15

HealthSouth Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	For the Year Ended December 31, 2015
				Adjustments
	As Reported			Gov't, Class Action, & Related Settlements			Prof. Fees - Acct., Tax, & Legal			Income Tax Valuation Allowance & Other Adj.		Mark-to-Market Adjustment for Stock Appreciation Rights			Transaction Costs			Loss on Early Exting. of Debt			As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$	682.5		$	—		$	—		$	—	$	—		$	—		$	—		$	682.5
Depreciation and amortization	(139.7		)	—			—			—		—			—			—			(139.7		)
Government, class action, and related settlements	(7.5		)	7.5			—			—		—			—			—			—
Professional fees - accounting, tax, and legal	(3.0		)	—			3.0			—		—			—			—			—
Loss on early extinguishment of debt	(22.4		)	—			—			—		—			—			22.4			—
Interest expense and amortization of debt discounts and fees	(142.9		)	—			—			—		—			—			—			(142.9		)
Stock-based compensation	(26.2		)	—			—			—		1.2			—			—			(25.0		)
Loss on disposal or impairment of assets	(2.6		)	—			—			—		—			—			—			(2.6		)
Transaction costs	(12.3		)	—			—			—		—			12.3			—			—
Income from continuing operations before income tax expense	325.9			7.5			3.0			—		1.2			12.3			22.4			372.3
Provision for income tax expense	(141.9		)	(3.0		)	(1.2		)	4.7		(0.5		)	(4.1		)	(9.0		)	(155.0		)
Income from continuing operations attributable to HealthSouth	$	184.0		$	4.5		$	1.8		$	4.7	$	0.7		$	8.2		$	13.4		$	217.3
Add: Interest on convertible debt, net of tax	9.4																				9.4
Numerator for diluted earnings per share	$	193.4																			$	226.7
Diluted earnings per share from continuing operations**	$	1.92		$	0.04		$	0.02		$	0.05	$	0.01		$	0.08		$	0.13		$	2.24
Diluted shares used in calculation	101.0

* Reconciliation to GAAP provided on page 17

** Adjusted EPS may not sum across due to rounding.

16

HealthSouth Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Income to Adjusted EBITDA

	For the Three Months Ended December 31,						For the Year Ended December 31,
	2016			2015			2016			2015
	(In Millions)
Net income	$	82.1		$	65.8		$	318.1		$	252.8
(Income) loss from discontinued operations, net of tax, attributable to HealthSouth	(0.3		)	(0.7		)	—			0.9
Provision for income tax expense	39.7			43.5			163.9			141.9
Interest expense and amortization of debt discounts and fees	41.6			44.6			172.1			142.9
Professional fees—accounting, tax, and legal	—			0.3			1.9			3.0
Government, class action, and related settlements	—			(0.5		)	—			7.5
Loss on early extinguishment of debt	—			2.4			7.4			22.4
Net noncash (gain) loss on disposal or impairment of assets	(1.3		)	2.4			0.7			2.6
Depreciation and amortization	43.8			41.4			172.6			139.7
Stock-based compensation expense	10.0			4.4			27.4			26.2
Net income attributable to noncontrolling interests	(16.8		)	(18.8		)	(70.5		)	(69.7		)
Transaction costs	—			6.7			—			12.3
Adjusted EBITDA	$	198.8		$	191.5		$	793.6		$	682.5

Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense

	For the Three Months Ended December 31,						For the Year Ended December 31,
	2016			2015			2016			2015
	In Millions
Total segment Adjusted EBITDA	$	225.6		$	216.4		$	899.6		$	774.1
General and administrative expenses	(36.8		)	(36.0		)	(133.4		)	(133.3		)
Depreciation and amortization	(43.8		)	(41.4		)	(172.6		)	(139.7		)
Gain (loss) on disposal or impairment of assets	1.3			(2.4		)	(0.7		)	(2.6		)
Government, class action, and related settlements	—			0.5			—			(7.5		)
Professional fees — accounting, tax, and legal	—			(0.3		)	(1.9		)	(3.0		)
Loss on early extinguishment of debt	—			(2.4		)	(7.4		)	(22.4		)
Interest expense and amortization of debt discounts and fees	(41.6		)	(44.6		)	(172.1		)	(142.9		)
Net income attributable to noncontrolling interests	16.8			18.8			70.5			69.7
Gain related to SCA equity interest	—			—			—			3.2
Income from continuing operations before income tax expense	$	121.5		$	108.6		$	482.0		$	395.6

17

HealthSouth Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

	For the Three Months Ended December 31,						For the Year Ended December 31,
	2016			2015			2016			2015
	(In Millions)
Net cash provided by operating activities	$	116.0		$	116.6		$	605.5		$	484.8
Provision for doubtful accounts	(14.5		)	(14.0		)	(61.2		)	(47.2		)
Professional fees—accounting, tax, and legal	—			0.3			1.9			3.0
Interest expense and amortization of debt discounts and fees	41.6			44.6			172.1			142.9
Equity in net income of nonconsolidated affiliates	2.5			2.4			9.8			8.7
Net income attributable to noncontrolling interests in continuing operations	(16.8		)	(18.8		)	(70.5		)	(69.7		)
Amortization of debt-related items	(3.5		)	(3.4		)	(13.8		)	(14.3		)
Distributions from nonconsolidated affiliates	(2.6		)	(3.2		)	(8.5		)	(7.7		)
Current portion of income tax expense	17.4			4.4			31.0			14.8
Change in assets and liabilities	41.3			53.6			102.9			147.1
Net premium paid on bond transactions	—			1.9			5.8			3.9
Windfall tax benefits from share-based compensation	17.3			—			17.3			—
Cash used in (provided by) operating activities of discontinued operations	0.1			(0.1		)	0.7			0.7
Transaction costs	—			6.7			—			12.3
Other	—			0.5			0.6			3.2
Consolidated Adjusted EBITDA	$	198.8		$	191.5		$	793.6		$	682.5

18

HealthSouth Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

	For the Three Months Ended December 31,						For the Year Ended December 31,
	2016			2015			2016			2015
	(In Millions)
Net cash provided by operating activities	$	116.0		$	116.6		$	605.5		$	484.8
Impact of discontinued operations	0.1			(0.1		)	0.7			0.7
Net cash provided by operating activities of continuing operations	116.1			116.5			606.2			485.5
Capital expenditures for maintenance	(39.7		)	(27.1		)	(104.2		)	(83.1		)
Dividends paid on convertible perpetual preferred stock	—			—			—			(3.1		)
Distributions paid to noncontrolling interests of consolidated affiliates	(15.4		)	(14.8		)	(64.9		)	(54.4		)
Items non-indicative of ongoing operations:
Net premium on bond issuance/repayment	—			1.9			5.8			4.0
Transaction costs and related assumed liabilities	—			6.5			0.8			28.3
Windfall tax benefits from share-based compensation	17.3			—			17.3			—
Cash paid for:
Professional fees—accounting, tax, and legal	—			0.3			1.9			4.1
Government, class action, and related settlements	—			(0.3		)	—			7.7
Adjusted free cash flow	$	78.3		$	83.0		$	462.9		$	389.0

For the three months ended December 31, 2016, net cash used in investing activities was $88.7 million and resulted primarily from capital expenditures and acquisitions of businesses offset by the proceeds from the disposal of the home health pediatric assets. Net cash used in financing activities during the three months ended December 31, 2016 was $63.2 million and resulted primarily from repurchases of common stock in the open market and cash dividends paid on common stock.

For the three months ended December 31, 2015, net cash used in investing activities was $950.4 million and resulted primarily from the acquisitions of Reliant and CareSouth. Net cash provided by financing activities during the three months ended December 31, 2015 was $93.8 million and resulted primarily from funding of the acquisitions of Reliant and CareSouth.

For the year ended December 31, 2016, net cash used in investing activities was $245.0 million and resulted primarily from capital expenditures and acquisitions of businesses offset by the proceeds from the disposal of the home health pediatric assets. Net cash used in financing activities during the year ended December 31, 2016 was $381.6 million and resulted primarily from the redemption of the Company's 7.75% Senior Notes due 2022, cash dividends paid on common stock, repurchases of common stock in the open market, and distributions to noncontrolling interests of consolidated affiliates.

For the year endedDecember 31, 2015,net cash used in investing activities was $1,129.8 and resulted primarily from the acquisitions of Reliant and CareSouth. Net cash provided by financing activities during the year endedDecember 31, 2015was $639.9 millionand resulted primarily from net debt issuances associated with the funding of the Reliant acquisition.

19

HealthSouth Corporation and Subsidiaries

Forward-Looking Statements

Statements contained in this press release which are not historical facts, such as those relating to financial guidance and assumptions, balance sheet and cash flow plans, and anticipated acquisitions, are forward-looking statements. In addition, HealthSouth, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and HealthSouth undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information, involve a number of risks and uncertainties, and relate to, among other things, future events, HealthSouth's plan to repurchase its debt or equity securities, dividend strategies, effective income tax rates, HealthSouth's business strategy, its financial plans, its future financial performance, its projected business results or model, its ability to return value to shareholders, its projected capital expenditures, its leverage ratio, its acquisition opportunities, and the impact of future legislation or regulation. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by HealthSouth include, but are not limited to, the price of HealthSouth's common stock as it affects the Company's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving HealthSouth, including its pending DOJ and HHS-OIG investigations and any matters related to yet undiscovered issues, if any, in acquired operations; HealthSouth's ability to attract and retain key management personnel, including as a part of executive management succession planning; any adverse effects on HealthSouth's stock price resulting from the integration of acquired operations; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of HealthSouth's information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability as well as unforeseen issues, if any, related to integration of acquired systems; the ability to successfully integrate acquired operations, including realization of anticipated tax benefits, revenues, and cost savings, minimizing the negative impact on margins arising from the changes in staffing and other operating practices, and avoidance of unforeseen exposure to liabilities; HealthSouth's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for HealthSouth's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction; competitive pressures in the healthcare industry and HealthSouth's response thereto; HealthSouth's ability to obtain and retain favorable arrangements with third-party payors; HealthSouth's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in HealthSouth's ability to recover improperly denied claims through the administrative appeals process on a timely basis; HealthSouth's ability to adapt to changes in the healthcare delivery system, including involvement in coordinated care initiatives or programs that may arise with its referral sources; HealthSouth's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and the impact on HealthSouth's labor expenses from potential union activity and staffing shortages; general conditions in the economy and capital markets, including any crisis resulting from uncertainty in the sovereign debt market; the increase in the costs of defending and insuring against alleged professional liability claims and HealthSouth's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in HealthSouth's SEC filings and other public announcements, including HealthSouth's Form 10‑K for the year ended December 31, 2016, when filed.

20

EX-99.2

Fourth Quarter 2016 Earnings Call February 22, 2017 SUPPLEMENTAL INFORMATION

2 The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect HealthSouth’s current outlook, views and plans with respect to future events, including legislative and regulatory developments, strategy, capital expenditures, acquisition and other development activities, cyber security, dividend strategies, repurchases of securities, effective tax rates, financial performance, financial assumptions, business model, balance sheet and cash flow plans, and shareholder value-enhancing transactions. These estimates, projections and other forward-looking information are based on assumptions HealthSouth believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material. There can be no assurance any estimates, projections or forward-looking information will be realized. All such estimates, projections and forward-looking information speak only as of the date hereof. HealthSouth undertakes no duty to publicly update or revise the information contained herein. You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the Form 10-K for the year ended December 31, 2016, when filed, and in other documents HealthSouth previously filed with the SEC, many of which are beyond HealthSouth’s control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein. Note Regarding Presentation of Non-GAAP Financial Measures The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. HealthSouth’s Form 8-K, dated February 21, 2017, to which the following supplemental information is attached as Exhibit 99.2, provides further explanation and disclosure regarding HealthSouth’s use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Forward-Looking Statements

3 Table of Contents Q4 2016 Summary................................................................................................................................................. 4-5 IRF-Home Health Clinical Collaboration ................................................................................................................ 6 Inpatient Rehabilitation Segment ........................................................................................................................... 7-8 Home Health & Hospice Segment ......................................................................................................................... 9-10 Earnings per Share ................................................................................................................................................ 11-12 Adjusted Free Cash Flow....................................................................................................................................... 13 Guidance................................................................................................................................................................ 14-15 Adjusted Free Cash Flow and Tax Assumptions.................................................................................................... 16 Free Cash Flow Priorities....................................................................................................................................... 17 Appendix Map of Locations.................................................................................................................................................... 19 Pre-Payment Claims Denials - Inpatient Rehabilitation Segment.......................................................................... 20 Expansion Activity .................................................................................................................................................. 21 Business Outlook ................................................................................................................................................... 22-24 Debt Schedule and Maturity Profile ....................................................................................................................... 25-26 New-Store/Same-Store IRF Growth ...................................................................................................................... 27 Payment Sources (Percent of Revenues).............................................................................................................. 28 Inpatient Rehabilitation Operational and Labor Metrics ......................................................................................... 29 Home Health & Hospice Operational Metrics ........................................................................................................ 30 Common Stock Warrants ....................................................................................................................................... 31 Share Information .................................................................................................................................................. 32 Segment Operating Results................................................................................................................................... 33-34 Reconciliations to GAAP........................................................................................................................................ 35-43 End Notes .............................................................................................................................................................. 44-45

4 Q4 2016 Summary Q4 Full Year (In Millions) Q4 2016 Q4 2015 % 2016 2015 % HealthSouth Consolidated Net operating revenues $ 949.9 $ 879.3 8.0% $ 3,707.2 $ 3,162.9 17.2% Adjusted EBITDA $ 198.8 $ 191.5 3.8% $ 793.6 $ 682.5 16.3% Inpatient Rehabilitation Segment Net operating revenues $ 767.6 $ 725.9 5.7% $ 3,021.1 $ 2,653.1 13.9% Adjusted EBITDA $ 197.6 $ 189.9 4.1% $ 797.2 $ 691.0 15.4% Home Health and Hospice Segment Net operating revenues $ 182.3 $ 153.4 18.8% $ 686.1 $ 509.8 34.6% Adjusted EBITDA $ 28.0 $ 26.5 5.7% $ 102.4 $ 83.1 23.1% Major takeaways: u Strong revenue growth in both segments Ÿ IRF growth primarily driven by pricing (net revenue per discharge increase of 4.8% in Q4 2016) Ÿ Home health and hospice growth primarily driven by volumes (admissions growth of 22.1% in Q4 2016; same-store = 14.0%) u Consolidated Adjusted EBITDA growth of 3.8% in Q4 2016 and 16.3% for full-year 2016 u Adjusted free cash flow increased 19.0% to $462.9 million in 2016 (up from $389.0 million in 2015) -see page 13. Reconciliations to GAAP provided on pages 35-43

5 Q4 2016 Summary (cont.) u Balance Sheet Ÿ Leverage ratio of 3.8x at year end; funded debt reduced by ~$155 million during full-year 2016 u Sold Pediatric Home Health Assets Ÿ Non-strategic assets Ÿ Pre-tax gain of ~$3 million Ÿ Tax expense of ~$6 million due to limited tax basis in assets sold Ÿ Represented ~$2 million of Adjusted EBITDA in 2016 u Expansion Activity (see page 21) Ÿ Opened 50-bed hospital in Modesto, CA Ÿ 10 IRF development projects underway (6 are joint ventures) Ÿ Expanded existing hospitals by 13 beds Ÿ Acquired four home health agencies — Springfield, VA; Laramie, WY; Cheyenne, WY; and Sarasota, FL — and opened a de novo home health agency in Georgetown, TX Ÿ Acquired one hospice location in Wheat Ridge, CO and opened one de novo hospice location in Nashville, TN u Shareholder Distributions Ÿ Repurchased 1.1 million shares of common stock for $41.5 million in Q4 2016 (full-year 2016 repurchases of 1.7 million shares for $64.1 million) Ÿ Paid quarterly cash dividend of $0.24 per share in October 2016 Ÿ Declared a $0.24 per share quarterly cash dividend in October 2016 which was paid in January 2017 u Expiration of Warrants in January 2017 (see page 31) Ÿ Issued a total of 699,346 new common shares ü 644,376 warrants exercised on a cash basis; received cash proceeds of $26.7 million ü 6,475,449 warrants exercised on a cashless basis; resulted in issuance of 54,970 common shares Ÿ 1,031,440 warrants expired unexercised

6 IRF-Home Health Clinical Collaboration (All Payors) Q4 2015 Q4 2016 10,360 10,074 2,735 3,963 20.9% Collaboration Rate 28.2% Collaboration Rate HealthSouth IRF Discharges to Non- Encompass Home Health HealthSouth IRF Discharges to Encompass Home Health Clinical collaboration rate with HealthSouth IRFs increased by 730 basis points over Q4 2015 u Overlap markets are defined as a HealthSouth IRF located within a 30- mile radius of an Encompass location u Currently, 59% of HealthSouth’s IRFs are located within overlap markets. u The Company’s clinical collaboration rate goal for overlap markets is 35% to 40% within the next three years. Overlap Markets

7 Inpatient Rehabilitation Segment - Revenue Q4 Q4 Favorable/ ($millions) 2016 2015 (Unfavorable) Net operating revenues: Inpatient $ 740.9 $ 696.8 6.3% Outpatient and other 26.7 29.1 (8.2%) Total segment revenue $ 767.6 $ 725.9 5.7% (Actual Amounts) Discharges 41,474 40,891 1.4% Same-store discharge growth 0.1% Net patient revenue / discharge $ 17,864 $ 17,040 4.8% u Revenue growth was driven by pricing and new-store volume growth. u Same-store discharge growth was impacted by certain market specific situations which the Company believes are temporary in nature. u New-store discharge growth resulted from joint ventures in Hot Springs, AR (February 2016), Bryan, TX (August 2016), and Broken Arrow, OK (August 2016) and the opening of wholly owned hospitals in Franklin, TN (December 2015) and Modesto, CA (October 2016). u Growth in revenue per discharge resulted from patient mix (higher percentage of stroke patients and integration of Reliant). u Outpatient and other revenue decrease was due primarily to the closure of six outpatient programs in certain markets.

8 Inpatient Rehabilitation Segment - Adjusted EBITDA Q4 % of Revenue Q4 % of Revenue($millions) 2016 2015 Net operating revenues $ 767.6 $ 725.9 Less: Provision for doubtful accounts (13.2) 1.7% (13.3) 1.8% Net operating revenues less provision for doubtful accounts 754.4 712.6 Operating expenses: Salaries and benefits (386.2) 50.3% (359.8) 49.6% Other operating expenses(a) (109.8) 14.3% (103.2) 14.2% Supplies (32.7) 4.3% (32.3) 4.4% Occupancy costs (15.2) 2.0% (14.5) 2.0% Hospital operating expenses (157.7) 20.5% (150.0) 20.7% Other income 0.8 1.3 Equity in nonconsolidated affiliates 2.4 2.3 Noncontrolling interests (16.1) (16.5) Segment Adjusted EBITDA $ 197.6 $ 189.9 Percent change 4.1% In arriving at Adjusted EBITDA, the following were excluded: (a) Loss on disposal or impairment of assets $ 2.0 $ 2.5 Segment Adjusted EBITDA for the quarter of $197.6 million - Salaries and benefits increased as a percent of revenue due to the ramp up of new stores and staffing increases at the Reliant hospitals since their acquisition on October 1, 2015. - Other operating expenses increased as a percent of revenue due to higher year-over- year self-insurance costs. - Bad debt expense as a percent of revenue decreased primarily due to the recovery of payments that were delayed for administrative reasons at the Company's largest Medicare Administrative Contractor in 2016; new pre-payment claim denials in Q4 2016 were lower than Q4 2015, but higher than Q3 2016 (see page 20). Reconciliations to GAAP provided on pages 35-43 - Supplies decreased as a percent of revenue due to continued supply chain efficiencies, including the continued transition of brand name drugs to generic.

9 Home Health and Hospice Segment - Revenue Q4 Q4 Favorable/ ($millions) 2016 2015 (Unfavorable) Net operating revenues: Home health revenue $ 165.2 $ 144.4 14.4% Hospice revenue 17.1 9.0 90.0% Total segment revenue $ 182.3 $ 153.4 18.8% (Actual Amounts) Admissions 27,957 22,892 22.1% Same-store admissions growth 14.0% Episodes 49,253 42,697 15.4% Same-store episode growth 12.4% Revenue per episode $ 3,023 $ 3,005 0.6% u Revenue growth was driven by strong same-store and new-store volume growth. Ÿ Approximately 320 basis points of same-store admission growth resulted from clinical collaboration with HealthSouth’s IRFs. u New-store admission and episode growth resulted primarily from the acquisition of CareSouth (acquired November 2, 2015). u Higher revenue per episode due to patient mix Ÿ Higher therapy mix (impacted by clinical collaboration) Ÿ Integration of CareSouth Ÿ Partially offset by Medicare reimbursement rate cuts

10 Q4 % of Revenue Q4 % of Revenue($millions) 2016 2015 Net operating revenues $ 182.3 $ 153.4 Less: Provision for doubtful accounts (1.3) 0.7% (0.7) 0.5% Net operating revenues less provision for doubtful accounts 181.0 152.7 Operating expenses:(a) Cost of services (89.7) 49.2% (73.0) 47.6% Support and overhead costs (62.7) 34.4% (51.0) 33.2% (152.4) 83.6% (124.0) 80.8% Equity in net income of nonconsolidated affiliates 0.1 0.1 Noncontrolling interests (0.7) (2.3) Segment Adjusted EBITDA $ 28.0 $ 26.5 Percent change 5.7% In arriving at Adjusted EBITDA, the following was excluded: (a) Gain on disposal or impairment of assets (3.3) (0.1) Home Health and Hospice Segment - Adjusted EBITDA Segment Adjusted EBITDA for the quarter of $28.0 million. - Operating expenses as a percent of net operating revenues increased due to Medicare reimbursement rate cuts, higher cost per visit (driven by an increased percentage of therapy patients), salary and benefit increases, and expenses related to the integration of CareSouth. * Reconciliation to GAAP provided on pages 29-31 Reconciliations to GAAP provided on pages 35-43

11 Earnings per Share - As Reported Q4 Year Ended (In Millions, Except Per Share Data) 2016 2015 2016 2015 Inpatient rehabilitation segment Adjusted EBITDA $ 197.6 $ 189.9 $ 797.2 $ 691.0 Home health and hospice segment Adjusted EBITDA 28.0 26.5 102.4 83.1 General and administrative expenses (26.8) (24.9) (106.0) (94.8) Gain related to SCA equity interest — — — 3.2 Consolidated Adjusted EBITDA 198.8 191.5 793.6 682.5 Interest expense and amortization of debt discounts and fees (41.6) (44.6) (172.1) (142.9) Depreciation and amortization (43.8) (41.4) (172.6) (139.7) Stock-based compensation expense (10.0) (4.4) (27.4) (26.2) Noncash gain (loss) on disposal or impairment of assets 1.3 (2.4) (0.7) (2.6) 104.7 98.7 420.8 371.1 Certain items non-indicative of ongoing operations: Government, class action, and related settlements — 0.5 — (7.5) Loss on early extinguishment of debt — (2.4) (7.4) (22.4) Professional fees - accounting, tax, and legal — (0.3) (1.9) (3.0) Transaction costs — (6.7) — (12.3) Pre-tax income 104.7 89.8 411.5 325.9 Income tax expense(1) (39.7) (43.5) (163.9) (141.9) Income from continuing operations* $ 65.0 $ 46.3 $ 247.6 $ 184.0 Interest and amortization on 2.0% Convertible Senior Subordinated Notes (net of tax)(2) 2.5 2.4 9.7 9.4 Diluted shares (see page 32) 99.2 100.6 99.5 101.0 Diluted earnings per share*(2) $ 0.68 $ 0.48 $ 2.59 $ 1.92 uEPS for Q4 2016 were impacted by: Ÿ Lower interest expense due to the redemptions of the 7.75% Senior Notes due 2022 Ÿ Lower state income tax rate driven by the Reliant and CareSouth acquisitions (Q4 2015 tax rate was higher than the statutory rate due to an increase in the Company’s valuation allowance related to certain state NOLs(3)) Ÿ Lower share count resulting from stock repurchases Ÿ Higher stock compensation due to the mark-to- market adjustment for stock appreciation rights(4) uEPS for FY 2016 were impacted by: Ÿ Higher depreciation and amortization resulting from acquisitions and capital investments Ÿ Higher interest expense related to the financing of the Reliant and CareSouth acquisitions (acquired Q4 2015) Ÿ Loss on early extinguishment of debt associated with the redemptions of the 7.75% Senior Notes due 2022 Ÿ Lower share count resulting from stock repurchases uEPS for 2015 were impacted by: Ÿ Loss on early extinguishment of debt associated with the redemption of the 8.125% Senior Notes due 2020 Ÿ General Medicine settlement Ÿ Reliant transaction costs * Earnings per share are determined using income from continuing operations attributable to HealthSouth. Refer to pages 44-45 for end notes.

12 Q4 Full Year 2016 2015 2016 2015 Earnings per share, as reported $ 0.68 $ 0.48 $ 2.59 $ 1.92 Adjustments, net of tax: Government, class action, and related settlements — — — 0.04 Professional fees — accounting, tax, and legal — — 0.01 0.02 Mark-to-market adjustment for stock appreciation rights(4) 0.02 — 0.01 0.01 Income tax valuation allowance and other tax adjustments (0.01) 0.05 (0.01) 0.05 Transaction costs — 0.05 — 0.08 Loss on early extinguishment of debt — 0.01 0.04 0.13 Sale of pediatric home health assets and hospital 0.03 — 0.02 — Adjusted earnings per share* $ 0.72 $ 0.59 $ 2.67 $ 2.24 Adjusted Earnings per Share(5) * Adjusted EPS may not sum due to rounding. See complete calculations of adjusted earnings per share on pages 40-43. Refer to pages 44-45 for end notes. Adjusted earnings per share removes from the GAAP earnings per share calculation the impact of items the Company believes are non-indicative of its ongoing operations.

13 Adjusted Free Cash Flow FY 2015 Adjusted EBITDA Working Capital and Other Cash Interest Expense Cash Tax Payments, Net of Refunds Maintenance Capital Expenditures Preferred Dividends Adjusted Free Cash Flow FY 2016 $389.0 $111.1 $33.0 ($29.8) ($22.4) ($21.1) $3.1 $462.9 2016 Adjusted Free Cash Flow(6) Reconciliations to GAAP provided on pages 35-43 Refer to pages 44-45 for end notes. u Adjusted free cash flow in 2016 grew 19.0% as a result of increased Adjusted EBITDA and favorable working capital changes. ü Working capital changes were mainly attributable to the recovery of payments that were delayed for administrative reasons at the Company’s largest MAC and the timing of payroll-related liabilities. ü Cash interest expense increased due to the financing of the Reliant and CareSouth acquisitions. ü Cash tax payments increased due to the exhaustion of the federal NOL and the tax impact of the gain on the sale of the home health pediatric assets. ü Increased maintenance capital expenditures resulted from growth in the IRF segment, an enhanced hospital maintenance program, and refurbishments at larger hospitals.

14 Refer to pages 44-45 for end notes. Guidance Adjusted EBITDA(7) Adjusted Earnings per Share from Continuing Operations Attributable to HealthSouth(5) Net Operating Revenues Net Operating Revenues $3,850 million to $3,950 million Adjusted EBITDA(7) $800 million to $820 million Adjusted Earnings per Share from Continuing Operations Attributable to HealthSouth(5) $2.61 to $2.73 $3,707.2 million $793.6 million $2.67 2017 Guidance 2016 Actuals

15 Guidance Considerations Inpatient Rehabilitation u Estimated 1.9% increase in Medicare pricing for Q1 through Q3; ~1.0% for Q4 (see page 23) u Salary increase of ~3.0% (see page 24) u 2016 included the benefit of a retroactive indirect medical education (“IME”) adjustment of ~$4 million at the former Reliant hospital in Woburn, MA. u Bad debt expense of 1.8% to 2.0% of net operating revenues Home Health and Hospice u Estimated 3.6%, or ~$21 million, net Medicare pricing reduction for CY 2017 (see page 23) u Salary increase of ~3.0% (see page 24) u Estimated incremental cost of $1.0 million to $1.5 million for the pre-claim review demonstration scheduled to begin in Florida on April 1, 2017 u Inclusive of home health and hospice acquisitions in 2017 (see page 17) u Sale of pediatric home health assets in Q4 2016; Pediatrics generated ~$2 million of Adjusted EBITDA in 2016 Consolidated u Diluted share count of ~100 million shares u Tax rate of approximately 40%

16 Adjusted Free Cash Flow(6) and Tax Assumptions Certain Cash Flow Items (millions) 2015 Actuals 2016 Actuals 2017 Assumptions • Cash interest expense (net of amortization of debt discounts and fees) $128.6 $158.4 $150 to $160 • Cash payments for taxes, net of refunds $9.4 $31.9 $120 to $175 • Working Capital and Other $69.2 $36.2 $50 to $70 • Maintenance CAPEX $83.1 $104.2 $130 to $150 • Dividends paid on preferred stock(8) $3.1 $— $0 • Adjusted Free Cash Flow $389.0 $462.9 $245 to $370 Reconciliations to GAAP provided on pages 35-43 Refer to pages 44-45 for end notes. * The Company has filed with the IRS for a tax accounting method change related to billings denied under pre-payment claims reviews that, if accepted, would replenish the gross federal NOL by ~$130 million. Exhaustion of the federal NOL at year-end 2016 excludes the impact of this filing. u Increased cash payments for taxes due to exhaustion of federal NOL as of December 31, 2016* u Increased maintenance capital expenditures due to growth in the Company, enhanced hospital maintenance program, and leasehold improvements and furnishings associated with the build-out of the Company’s new home office location (building will be leased)

17 Note: 2015 amount for debt borrowings included ~$208 million related to the Reliant hospitals' capital lease obligations.See the debt schedule on page 25. Refer to pages 44-45 for end notes. Free Cash Flow Priorities (In Millions) 2015 2016 2017 Actuals Actuals Assumptions IRF bed expansions $20.8 $19.1 $30 to $40 New IRF’s - De novos 47.8 72.6 85 to 105 - Acquisitions 786.2 — TBD - Replacement hospitals — 11.1 10 to 20 New home health and hospice acquisitions 200.2 48.1 50 to 100 $1,055.0 $150.9 $175 to $265, excluding IRF acquisitions 2015 2016 2017 Actuals Actuals Assumptions Debt (borrowings) redemptions, net $(1,060.3) $155.1 $TBD Cash dividends on common stock(10) 77.2 83.8 ~$87 Common stock repurchases 45.3 65.6 TBD $(937.8) $304.5 $TBD Shareholder Distributions Growth in Core Business Debt Reduction Highest Priorit y The Company has ~$39 million of contractual debt repayment obligations in 2017.(9) ~$96 million authorization remaining as of December 31, 2016 Quarterly cash dividend currently set at $0.24 per common share

Appendix

19 HealthSouth: A Leading Provider of Post-Acute Care 59% of HealthSouth's IRFs are located within a 30-mile radius of an Encompass location. Inpatient Rehabilitation Portfolio - As of December 31, 2016 123 Inpatient Rehabilitation Hospitals • 37 operate as joint ventures with acute care hospitals 30 Number of States (plus Puerto Rico) ~ 28,000 Employees Key Statistics - Full Year 2016 ~ $3.0 Billion Revenue 165,305 Inpatient Discharges 640,702 Outpatient Visits Note: One of the 123 IRFs and two of the 188 adult home health locations are nonconsolidated. These locations are accounted for using the equity method of accounting. Encompass Home Health and Hospice Portfolio – As of December 31, 2016 188 Home Health Locations 35 Hospice Locations 25 Number of States ~ 7,700 Employees Key Statistics - Full Year 2016 ~ $686 million Revenue 185,737 Home Health Episodes 3,337 Hospice Admissions IRF Market Share Largest owner & operator of IRFs 21% of Licensed Beds 28% of Medicare Patients Served Home Health and Hospice Market Share 4th largest provider of Medicare-certified skilled home health services

20 Pre-Payment Claims Denials - Inpatient Rehabilitation Segment Impact to Income Statement Period New Denials Collections of Previously Denied Claims Bad Debt Expense for New Denials Update of Reserve for Prior Denials (In Millions) Q4 2016 $17.8 $(4.4) $5.4 $0.5 Q3 2016 15.7 (8.5) 4.6 — Q2 2016 18.7 (4.9) 4.6 — Q1 2016 22.7 (8.4) 6.0 — Q4 2015 22.5 (4.1) 5.6 (1.3) Q3 2015 22.0 (4.1) 5.9 (1.1) Q2 2015 18.2 (3.8) 4.9 — Q1 2015 16.3 (3.0) 4.2 — Q4 2014 22.0 (6.6) 6.2 (3.2) Q3 2014 15.8 (0.5) 1.7 — Q2 2014 7.1 (1.7) 3.0 — Impact to Balance Sheet Dec. 30, 2016 Dec. 31, 2015 Dec. 31, 2014 (In Millions) Pre-payment claims denials $ 159.7 $ 114.8 $ 59.3 Recorded reserves (47.9) (31.2) (22.8) Net accounts receivable from pre-payment claims denials $ 111.8 $ 83.6 $ 36.5 Background Ÿ For several years, under programs designated as “widespread probes,” certain Medicare Administrative Contractors (“MACs”) have conducted pre-payment claim reviews and denied payment for certain diagnosis codes. – Pre-payment claim denials increased for IRFs during 2014 and 2015 due to a widespread review of neurological billing codes and expansion of ongoing lower extremity code denials. Ÿ HealthSouth appeals most denials. On claims it takes to an administrative law judge (“ALJ”), HealthSouth historically has experienced an approximate 70% success rate. – MACs identify medical documentation issues as a leading basis for denials. – HealthSouth's investment in clinical information systems and its medical services department has further improved its documentation and reduced technical denials. – However, MACs and other HHS contractors continue to issue denials without regulatory basis. Ÿ By statute, ALJ decisions are due within 90 days of a request for hearing, but appeals are taking years. HHS has proposed rule changes to address the backlog of appeals, but their effect is uncertain. Ÿ A federal court recently ordered HHS to eliminate the backlog by the end of calendar year 2020. HHS has appealed the order. Ÿ All Medicare providers continue to experience delays. The backlog is growing because the ALJs receive one year's worth of appeals every four to six weeks, according to HHS. – Currently, ALJs are hearing HealthSouth appeals from claims denied up to five years ago. HealthSouth reserves for pre-payment claim denials via the provision for doubtful accounts upon notice from a MAC that a claim is under review.

21 Expansion Activity Inpatient Rehabilitation Facilities # of New Beds 2016 2017 2018 De Novo: Modesto, CA 50 — — Pearland, TX — 40 — Murrieta, CA — — 50 Shelby County, AL — — 34 Hilton Head, SC — — 38 Joint Ventures: Hot Springs, AR 40 — — Bryan, TX 49 — — Broken Arrow, OK* 22 18 — Westerville, OH — 60 — Jackson, TN — 48 — Gulfport, MS — 33 — Murrells Inlet, SC — — 29 Winston-Salem, NC — — 68 Bed Expansions, net** 83 ~150 ~100 244 349 319 Little River, SC (46 beds pending CON approval) * ** Operating a unit in place (22 beds) while completing a de novo (40 beds) for a net increase of 18 beds in 2017. Net bed expansions in each year may change due to the timing of certain regulatory approvals and/or construction delays. 2016 does not include impact of sale of 61-bed hospital in Beaumont, TX or closure of 83-bed hospital in Austin, TX. Q4 2016 acquisition highlights: u Acquired Summit Home Health Care (two home health agencies in WY) u Opened one de novo home health agency in Georgetown, TX and one de novo hospice location in Nashville, TN u Acquired one home health agency in Springfield, VA u Acquired one home health agency in Sarasota, FL u Acquired one hospice location in Wheat Ridge, CO Q4 2016 expansion activity highlights: u Opened new 50-bed hospital in Modesto, CA in October 2016 u Received CON approval to build a 68-bed hospital in Winston- Salem, NC (joint venture with Novant Health) u Expanded existing hospital in Jonesboro, AR by 13 beds u Entered into a joint venture with Memorial Hospital at Gulfport to own and operate an existing 33-bed inpatient rehabilitation unit in Gulfport, MS2 3 4 5 6 10 IRF DevelopmentProjects Underway 2 New States 8 9 Home Health and Hospice # of locations December 31, 2015 213 Acquisitions 13 De Novo 5 Merged / Closed Locations (8) December 31, 2016 223 1 S7 Winston-Salem, NC 10 9

22 • Same-store IRF growth • New-store IRF growth (de novos and acquisitions) • Same-store home health and hospice growth • New-store home health and hospice growth (acquisitions) Core Growth Strong Balance Sheet Key Operational Initiatives Shareholder Distributions Opportunistic Growth Business Outlook 2017 to 2019* 2017 2018 2019 Business Model • Adjusted EBITDA CAGR: 5% - 9%** • Strong free cash flow generation • Quarterly cash dividends • Opportunistic repurchases - (~$96 million authorization remaining as of December 31, 2016) • Develop and implement risk sharing strategies • Enhance clinical collaboration between HealthSouth and Encompass • Refine and expand clinical data analytics utilization to further improve patient outcomes • Leverage clinical expertise to increase stroke admissions • Complete installation of EMR and enhance utilization via continuous in-service upgrades • Target leverage of 3.5x to 3.8x by year end, subject to opportunities for creating shareholder value Strategy Componen t • Consider acquisitions of other complementary businesses • Target leverage of 3.5x or less, subject to opportunities for creating shareholder value * If legislation affecting Medicare is passed, HealthSouth will evaluate its effect on its business model. ** This is a multi-year CAGR; annual results may fall outside the range.

23 • 10% to15% annual episode growth • Includes $35-$40 million per annum in agency acquisitions Volume (Includes New Stores) Inpatient Rehabilitation Home Health & Hospice Medicare Pricing Approx. 73% of Revenue Approx. 83% of Revenue FY 2017 Q416-Q317 FY 2018 Q417-Q318(11) FY 2019 Q418-Q319 Mgmt. Estimate CY 2017 Q117-Q417 CY 2018 Q118-Q418(11) CY 2019 Q119-Q419 Mgmt. Estimate Market basket update 2.7% 1.0% 3.3% 2.8% 1.0% 3.1% Healthcare reform reduction (75) bps - (75) bps - - - Healthcare reform rebasing adjustment - - - (2.3%) - Coding intensity reduction - - - (0.9%) (0.9%) - Expiration of rural add-on - - - - Approx.(0.7%) - Healthcare reform productivity adjustment (30) bps - (100) bps (30) bps - (100) bps Net impact - all providers 1.65% 1.0% 1.55% (0.7%) (0.6%) 2.1% Outlier fixed dollar loss adjustment - - - (0.1%) - - Impact from case mix re-weighting - - - (0.9%) - - Impact from change in outlier calculation - - - (1.9%) - - Estimated impact to HealthSouth(12) 1.9% (3.6%) Medicare Advantage & Managed Care Pricing Approx. 19% of Revenue Approx. 13% of Revenue Expected Increases 2-4% 2-4% 2-4% 0-2% 0-2% 0-2% Business Outlook 2017 to 2019: Revenue Assumptions • 3+% annual discharge growth • 10+% annual episode growth Refer to pages 44-45 for end notes.

24 Inpatient Rehabilitation Home Health and Hospice Business Outlook 2017 to 2019: Labor and Other Expense Assumptions Salaries & Benefits ~70% Hospital Expenses ~30% Salaries and Benefits 2017 2018 2019 Salary increases 2.75-3.25% 2.75-3.25% 2.75-3.25% Benefit costs increases 5-10% 5-10% 5-10% Hospital Expenses • Other operating expenses and supply costs tracking with inflation Salaries & Benefits ~85% Other Expenses ~15% Home Health Expenses • Other operating expenses and supply costs tracking with inflation Percent of Salaries & Benefits Salaries ~ 90% Benefits ~10%

25 Debt Schedule Change in Dec. 31, Dec. 31, Debt vs. ($millions) 2016 2015 YE 2015 Advances under $600 million revolving credit facility, July 2020 - LIBOR +200bps $ 152.0 $ 130.0 $ 22.0 Term loan facility, July 2020 - LIBOR +200bps 421.2 443.3 (22.1) Bonds Payable: 7.75% Senior Notes due 2022 — 174.3 (174.3) 5.125% Senior Notes due 2023 295.3 294.6 0.7 5.75% Senior Notes due 2024 1,193.2 1,192.6 0.6 5.75% Senior Notes due 2025 343.9 343.4 0.5 2.0% Convertible Senior Subordinated Notes due 2043 275.7 265.9 9.8 Other notes payable 55.8 39.2 16.6 Capital lease obligations 279.3 288.2 (8.9) Long-term debt $ 3,016.4 $ 3,171.5 $ (155.1) Debt to Adjusted EBITDA 3.8x 4.6x Reconciliations to GAAP provided on pages 35-43

26 2016 2019 2020 2020 2021 2022 2023 2024 2025 2043 $350 Senior Notes 5.75% $1,200 Senior Notes 5.75% $320 Conv. Sr. Sub. Notes 2.0% $300 Senior Notes 5.125% $152 Drawn + $33 reserved for LC’s Holders have a put option in 2020 As of December 31, 2016* Debt Maturity Profile - Face Value ($ in millions) $415 Available Callable beginning November 2017 HealthSouth is positioned with a cost-efficient, flexible capital structure. Callable beginning March 2018 Revolver Revolver Capacity $421 Term Loans Callable beginning September 2020 * This chart does not include ~$279 million of capital lease obligations or ~$56 million of other notes payable. See the debt schedule on page 25. No significant debt maturities prior to 2020

27 25.0 20.0 15.0 10.0 5.0 0.0 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 New-Store/Same-Store IRF Growth Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 Fairlawn(13) 0.6% 1.9% 1.9% 2.0% 1.1% New Store 2.0% 1.0% —% 0.6% 1.8% 4.4% 5.7% 15.6% 14.2% 11.7% 10.7% 1.3% Same Store* 0.4% 1.4% 1.9% 2.2% 2.9% 2.8% 3.9% 3.0% 2.8% 1.9% 1.9% 0.1% Total by Qtr. 2.4% 3.0% 3.8% 4.7% 6.7% 8.3% 9.6% 18.6% 17.0% 13.6% 12.6% 1.4% Total by Year 3.5% 10.9% 10.8% Same-Store Year* 1.3% 3.2% 1.7% Same-Store Year UDS(14) (0.2)% 1.3% (0.6)% Altamonte Springs, FL (50 beds) Johnson City, TN (26 beds) Newnan, GA (50 beds) Middletown, DE (34 beds) Reliant (857 beds) Franklin, TN (40 beds) Lexington, KY (158 beds) Savannah, GA (50 beds) Hot Springs, AR (40 beds) Bryan, TX (49 beds) Broken Arrow, OK (22 beds) * Includes consolidated HealthSouth inpatient rehabilitation hospitals classified as same store during each period Refer to pages 44-45 for end notes. Modesto, CA (50 beds)

28 Payment Sources (Percent of Revenues) Inpatient Rehabilitation Segment Home Health and Hospice Segment Consolidated Q4 Q4 Q4 Full Year 2016 2015 2016 2015 2016 2015 2016 2015 Medicare 73.3% 73.6% 84.3% 82.6% 75.3% 75.2% 75.2% 74.9% Medicare Advantage 7.8% 7.8% 8.7% 9.2% 8.0% 8.0% 7.9% 7.9% Managed care 10.9% 10.7% 3.9% 2.9% 9.6% 9.4% 9.8% 9.8% Medicaid 3.0% 2.5% 3.0% 5.1% 3.0% 2.9% 3.2% 3.0% Other third-party payors 1.9% 2.3% —% —% 1.5% 1.9% 1.4% 1.7% Workers’ compensation 1.1% 1.1% —% —% 0.9% 0.9% 0.8% 0.9% Patients 0.7% 0.7% —% 0.1% 0.6% 0.6% 0.5% 0.6% Other income 1.3% 1.3% 0.1% 0.1% 1.1% 1.1% 1.2% 1.2% Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%

29 Inpatient Rehabilitation Operational and Labor Metrics Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2016 2016 2016 2016 2015 2015 2015 2015 2016 2015 (In Millions) Net patient revenue- inpatient $ 740.9 $ 724.1 $ 721.2 $ 719.4 $ 696.8 $ 625.1 $ 618.7 $ 606.6 $ 2,905.5 $ 2,547.2 Net patient revenue- outpatient and other 26.7 27.6 31.4 29.8 29.1 26.5 26.6 23.7 115.6 105.9 Net operating revenues $ 767.6 $ 751.7 $ 752.6 $ 749.2 $ 725.9 $ 651.6 $ 645.3 $ 630.3 $ 3,021.1 $ 2,653.1 (Actual Amounts) Discharges(15) 41,474 41,368 41,365 41,098 40,891 36,746 36,408 35,116 165,305 149,161 Net patient revenue per discharge $ 17,864 $ 17,504 $ 17,435 $ 17,505 $ 17,040 $ 17,011 $ 16,994 $ 17,274 $ 17,577 $ 17,077 Outpatient visits 154,311 158,981 164,761 162,649 163,119 138,121 144,914 131,353 640,702 577,507 Average length of stay 12.8 12.7 12.6 12.9 12.6 12.9 13.0 13.3 12.8 12.9 Occupancy % 67.8% 67.8% 68.2% 68.9% 66.4% 69.6% 70.4% 72.8% 67.8% 62.8% # of licensed beds* 8,504 8,441 8,430 8,481 8,404 7,422 7,374 7,100 8,504 8,404 Occupied beds 5,766 5,723 5,749 5,843 5,580 5,166 5,191 5,169 5,766 5,278 Full-time equivalents (FTEs)(16) 19,930 19,663 19,503 19,352 19,136 17,782 17,601 17,002 19,612 17,880 Contract labor 245 241 205 194 152 141 118 116 221 132 Total FTE and contract labor 20,175 19,904 19,708 19,546 19,288 17,923 17,719 17,118 19,833 18,012 EPOB(17) 3.50 3.48 3.43 3.35 3.46 3.47 3.41 3.31 3.44 3.41 * The decrease in licensed beds from Q1 2016 to Q2 2016 was due to the sale of the hospital in Beaumont, TX (61 beds). Refer to pages 44-45 for end notes.

30 Home Health and Hospice Operational Metrics Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2016 2016 2016 2016 2015 2015 2015 2015 2016 2015 (In Millions) Net home health revenue $ 165.2 $ 162.0 $ 157.1 $ 150.9 $ 144.4 $ 118.3 $ 111.5 $ 103.9 $ 635.2 $ 478.1 Net hospice and other revenue 17.1 13.1 11.0 9.7 9.0 8.7 7.6 6.4 50.9 31.7 Net operating revenues $ 182.3 $ 175.1 $ 168.1 $ 160.6 $ 153.4 $ 127.0 $ 119.1 $ 110.3 $ 686.1 $ 509.8 Home Health: (Actual Amounts) Admissions(18) 27,957 27,239 25,753 25,763 22,892 18,076 16,862 16,499 106,712 74,329 Recertifications 21,422 20,888 20,432 19,453 18,909 16,542 15,103 14,485 82,195 65,039 Episodes 49,253 46,866 45,774 43,844 42,697 33,542 31,817 29,512 185,737 137,568 Average revenue per episode $ 3,023 $ 3,032 $ 3,033 $ 3,035 $ 3,005 $ 3,123 $ 3,082 $ 3,102 $ 3,031 $ 3,072 Episodic visits per episode 18.4 19.0 18.9 19.1 18.2 19.6 19.4 19.6 18.8 19.1 Total visits 1,033,502 1,001,021 967,968 937,804 862,224 721,055 675,095 630,999 3,940,295 2,889,373 Cost per visit $ 76 $ 75 $ 73 $ 73 $ 73 $ 72 $ 71 $ 71 $ 74 $ 72 Hospice: Admissions(19) 996 832 785 724 614 620 594 624 3,337 2,452 Patient days 104,183 83,628 71,277 63,431 59,100 55,627 49,272 40,898 322,519 204,898 Revenue per day $ 164 $ 157 $ 154 $ 153 $ 155 $ 156 $ 154 $ 156 $ 158 $ 155 Refer to pages 44-45 for end notes.

31 Common Stock Warrants On September 30, 2009, HealthSouth issued 8,151,265 warrants in satisfaction of its obligation under the comprehensive settlement of the 2003 consolidated class action suit brought by the Company’s stockholders and bondholders. Under the terms of the agreement, the warrants were exercisable at a price of $41.40 per share by means of cash or cashless exercise at the option of the holder. The warrants expired at 5 p.m. EST on January 17, 2017. Warrants Shares Issued Cash Received (Millions) Outstanding Warrants 8,151,265 — $ — Cash Exercise* (644,376) 644,376 26.7 Cashless Exercise** (6,475,449) 54,970 — Expired (Unexercised) (1,031,440) — — As of January 17, 2017 — 699,346 $ 26.7 HealthSouth repurchased approximately 1.1 million shares of common stock in Q4 2016, resulting in a net reduction to the diluted share count of approximately 0.4 million shares after the exercise of the above warrants in January 2017. * In a cash exercise, the warrant holder exchanges one warrant for one share of common stock and tenders cash of $41.40 per share. ** If the holder chooses a cashless exercise, the company issues the number of shares equal in value to the in-the-money amount of the warrant. No cash is received from the holder.

32 Share Information Weighted Average for the Period Q4 Full Year (Millions) 2016 2015 2016 2015 2014 Basic shares outstanding(8) 88.6 90.1 89.1 89.4 86.8 Convertible perpetual preferred stock(8) — — — 1.0 3.2 Convertible senior subordinated notes(20) 8.6 8.4 8.5 8.3 8.2 Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants(21) 2.0 2.1 1.9 2.3 2.5 Diluted shares outstanding 99.2 100.6 99.5 101.0 100.7 End of Period Q4 Full Year (Millions) 2016 2015 2016 2015 2014 Basic shares outstanding(8) 88.3 89.3 88.3 89.3 86.6 Approx. Approx. Date Conversion Rate Conversion Price Convertible senior subordinated notes(20) 1/3/17 26.9106 $37.16 Refer to pages 44-45 for end notes.

33 Segment Operating Results Q4 2016 Q4 2015 IRF Home Health and Hospice Reclasses HealthSouthConsolidated IRF Home Health and Hospice Reclasses HealthSouthConsolidated Net operating revenues $ 767.6 $ 182.3 $ — $ 949.9 $ 725.9 $ 153.4 $ — $ 879.3 Less: Provision for doubtful accounts (13.2) (1.3) — (14.5) (13.3) (0.7) — (14.0) 754.4 181.0 — 935.4 712.6 152.7 — 865.3 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (386.2) — (130.1) (516.3) (359.8) — (107.0) (466.8) Other operating expenses(a) (109.8) — (16.6) (126.4) (103.2) — (12.4) (115.6) Supplies (32.7) — (3.1) (35.8) (32.3) — (2.3) (34.6) Occupancy (15.2) — (2.6) (17.8) (14.5) — (2.3) (16.8) Home Health and Hospice: Cost of services sold (excluding depreciation and amortization) — (89.7) 89.7 — — (73.0) 73.0 — Support and overhead costs — (62.7) 62.7 — — (51.0) 51.0 — (543.9) (152.4) — (696.3) (509.8) (124.0) — (633.8) Other income 0.8 — — 0.8 1.3 — — 1.3 Equity in net income of nonconsolidated affiliates 2.4 0.1 — 2.5 2.3 0.1 — 2.4 Noncontrolling interest (16.1) (0.7) — (16.8) (16.5) (2.3) — (18.8) Segment Adjusted EBITDA $ 197.6 $ 28.0 $ — 225.6 $ 189.9 $ 26.5 $ — 216.4 General and administrative expenses(b)(c) (26.8) (24.9) Adjusted EBITDA $ 198.8 $ 191.5 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal or impairment of assets $ 2.0 $ (3.3) $ — $ (1.3) $ 2.5 $ (0.1) $ — $ 2.4 (b) Transaction costs — — — — — — — 6.7 (c) Stock-based compensation — — — 10.0 — — — 4.4 Reconciliations to GAAP provided on pages 35-43

34 Segment Operating Results Year Ended December 31, 2016 Year Ended December 31, 2015 IRF Home Health and Hospice Reclasses HealthSouthConsolidated IRF Home Health and Hospice Reclasses HealthSouthConsolidated Net operating revenues $ 3,021.1 $ 686.1 $ — $ 3,707.2 $ 2,653.1 $ 509.8 $ — $ 3,162.9 Less: Provision for doubtful accounts (57.0) (4.2) — (61.2) (44.7) (2.5) — (47.2) 2,964.1 681.9 — 3,646.0 2,608.4 507.3 — 3,115.7 Operating Expenses: — Inpatient Rehabilitation: — Salaries and benefits (1,493.4) — (492.5) (1,985.9) (1,310.6) — (360.2) (1,670.8) Other operating expenses(a) (431.5) — (59.9) (491.4) (387.7) — (41.8) (429.5) Supplies (128.8) — (11.2) (140.0) (120.9) — (7.8) (128.7) Occupancy (61.2) — (10.1) (71.3) (46.2) — (7.7) (53.9) Home Health and Hospice: Cost of services sold (excluding depreciation and amortization) — (336.5) 336.5 — — (244.8) 244.8 — Support and overhead costs — (237.2) 237.2 — — (172.7) 172.7 — (2,114.9) (573.7) — (2,688.6) (1,865.4) (417.5) — (2,282.9) Other income 2.9 — — 2.9 2.3 — — 2.3 Equity in net income of nonconsolidated affiliates 9.1 0.7 — 9.8 8.6 0.1 — 8.7 Noncontrolling interest (64.0) (6.5) — (70.5) (62.9) (6.8) — (69.7) Segment Adjusted EBITDA $ 797.2 $ 102.4 $ — 899.6 $ 691.0 $ 83.1 $ — 774.1 General and administrative expenses(b)(c) (106.0) (94.8) Gain related to SCA equity interest — 3.2 Adjusted EBITDA $ 793.6 $ 682.5 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal or impairment of assets $ 4.3 $ (3.6) $ — $ 0.7 $ 2.8 $ (0.2) $ — $ 2.6 (b) Transaction costs — — — — — — — 12.3 (c) Stock-based compensation — — — 27.4 — — — 26.2 Reconciliations to GAAP provided on pages 35-43

35 Reconciliation of Net Income to Adjusted EBITDA(7) 2016 Q1 Q2 Q3 Q4 Full Year (in millions, except per share data) Total Per Share Total Per Share Total Per Share Total Per Share Total Per Share Net Income $ 76.7 $ 81.2 $ 78.1 $ 82.1 $ 318.1 Loss (income) from disc ops, net of tax, attributable to HealthSouth 0.1 0.1 0.1 (0.3) — Net income attributable to noncontrolling interests (18.7) (18.6) (16.4) (16.8) (70.5) Income from continuing operations attributable to HealthSouth* 58.1 $ 0.61 62.7 $ 0.65 61.8 $ 0.64 65.0 $ 0.68 247.6 $ 2.59 Pro fees - acct, tax, and legal 0.2 1.7 — — 1.9 Provision for income tax expense 39.7 42.4 42.1 39.7 163.9 Interest expense and amortization of debt discounts and fees 44.6 43.4 42.5 41.6 172.1 Depreciation and amortization 42.4 42.9 43.5 43.8 172.6 Loss on early extinguishment of debt 2.4 2.4 2.6 — 7.4 Net noncash loss (gain) on disposal or impairment of assets 0.2 0.2 1.6 (1.3) 0.7 Stock-based compensation expense 4.5 8.6 4.3 10.0 27.4 Adjusted EBITDA $ 192.1 $ 204.3 $ 198.4 $ 198.8 $ 793.6 Weighted average common shares outstanding: Basic 89.5 89.3 89.1 88.6 89.1 Diluted 99.4 99.4 99.4 99.2 99.5 * Per share amounts for each period presented are based on diluted weighted-average shares outstanding. Refer to pages 44-45 for end notes.

36 Reconciliation of Net Income to Adjusted EBITDA(7) 2015 Q1 Q2 Q3 Q4 Full Year (in millions, except per share data) Total Per Share Total Per Share Total Per Share Total Per Share Total Per Share Net Income $ 59.0 $ 60.2 $ 67.8 $ 65.8 $ 252.8 Loss (income) from disc ops, net of tax, attributable to HealthSouth 0.3 1.6 (0.3) (0.7) 0.9 Net income attributable to noncontrolling interests (16.5) (17.3) (17.1) (18.8) (69.7) Income from continuing operations attributable to HealthSouth* 42.8 $ 0.44 44.5 $ 0.47 50.4 $ 0.52 46.3 $ 0.48 184.0 $ 1.92 Gov’t, class action, and related settlements 8.0 — — (0.5) 7.5 Pro fees - acct, tax, and legal 2.2 0.1 0.4 0.3 3.0 Provision for income tax expense 30.3 32.2 35.9 43.5 141.9 Interest expense and amortization of debt discounts and fees 31.8 30.9 35.6 44.6 142.9 Depreciation and amortization 31.9 32.7 33.7 41.4 139.7 Loss on early extinguishment of debt 1.2 18.8 — 2.4 22.4 Net noncash (gain) loss on disposal or impairment of assets (1.5) 0.8 0.9 2.4 2.6 Stock-based compensation expense 9.4 6.2 6.2 4.4 26.2 Transaction costs — 3.3 2.3 6.7 12.3 Adjusted EBITDA $ 156.1 $ 169.5 $ 165.4 $ 191.5 $ 682.5 Weighted average common shares outstanding: Basic 87.1 89.8 90.6 90.1 89.4 Diluted 101.1 101.5 101.5 100.6 101.0 * Per share amounts for each period presented are based on diluted weighted-average shares outstanding. Refer to pages 44-45 for end notes.

37 Net Cash Provided by Operating Activities Reconciled to Adjusted EBITDA Q4 Full Year (Millions) 2016 2015 2016 2015 Net cash provided by operating activities $ 116.0 $ 116.6 $ 605.5 $ 484.8 Provision for doubtful accounts (14.5) (14.0) (61.2) (47.2) Professional fees—accounting, tax, and legal — 0.3 1.9 3.0 Interest expense and amortization of debt discounts and fees 41.6 44.6 172.1 142.9 Equity in net income of nonconsolidated affiliates 2.5 2.4 9.8 8.7 Net income attributable to noncontrolling interests in continuing operations (16.8) (18.8) (70.5) (69.7) Amortization of debt-related items (3.5) (3.4) (13.8) (14.3) Distributions from nonconsolidated affiliates (2.6) (3.2) (8.5) (7.7) Current portion of income tax expense 17.4 4.4 31.0 14.8 Change in assets and liabilities 41.3 53.6 102.9 147.1 Net premium paid on bond transactions — 1.9 5.8 3.9 Windfall tax benefits from share-based compensation 17.3 — 17.3 — Cash used in (provided by) operating activities of discontinued operations 0.1 (0.1) 0.7 0.7 Transaction costs — 6.7 — 12.3 Other — 0.5 0.6 3.2 Adjusted EBITDA $ 198.8 $ 191.5 $ 793.6 $ 682.5

38 Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense Three Months Ended Year Ended December 31, December 31, 2016 2015 2016 2015 In Millions Total segment Adjusted EBITDA $ 225.6 $ 216.4 $ 899.6 $ 774.1 General and administrative expenses (36.8) (36.0) (133.4) (133.3) Depreciation and amortization (43.8) (41.4) (172.6) (139.7) Gain (loss) on disposal or impairment of assets 1.3 (2.4) (0.7) (2.6) Government, class action, and related settlements — 0.5 — (7.5) Professional fees - accounting, tax, and legal — (0.3) (1.9) (3.0) Loss on early extinguishment of debt — (2.4) (7.4) (22.4) Interest expense and amortization of debt discounts and fees (41.6) (44.6) (172.1) (142.9) Net income attributable to noncontrolling interests 16.8 18.8 70.5 69.7 Gain related to SCA equity interest — — — 3.2 Income from continuing operations before income tax expense $ 121.5 $ 108.6 $ 482.0 $ 395.6

39 Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow(6) Q4 Full Year ($millions) 2016 2015 2016 2015 2014 Net cash provided by operating activities $ 116.0 $ 116.6 $ 605.5 $ 484.8 $ 444.9 Impact of discontinued operations 0.1 (0.1) 0.7 0.7 1.2 Net cash provided by operating activities of continuing operations 116.1 116.5 606.2 485.5 446.1 Capital expenditures for maintenance (39.7) (27.1) (104.2) (83.1) (92.0) Dividends paid on convertible perpetual preferred stock(8) — — — (3.1) (6.3) Distributions paid to noncontrolling interests of consolidated affiliates (15.4) (14.8) (64.9) (54.4) (54.1) Items non-indicative of ongoing operations: Cash paid for professional fees - accounting, tax, and legal — 0.3 1.9 4.1 8.6 Transaction costs and related assumed liabilities — 6.5 0.8 28.3 2.0 Net premium on bond issuance/repayment — 1.9 5.8 4.0 4.3 Windfall tax benefits from share-based compensation 17.3 — 17.3 — — Cash (received) paid for government, class action, and related settlements — (0.3) — 7.7 2.7 Adjusted free cash flow $ 78.3 $ 83.0 $ 462.9 $ 389.0 $ 311.3 Cash dividends on common stock $ 21.4 $ 21.0 $ 83.8 $ 77.2 $ 65.8 Refer to pages 44-45 for end notes.

40 For the Three Months Ended December 31, 2016 Adjustments As Reported Mark-to- Market Adjustment for Stock Appreciation Rights Sale of Pediatric Home Health Assets and Hospital Income Tax Valuation and Other Adjustments As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 198.8 $ — $ — $ — $ 198.8 Depreciation and amortization (43.8) — — — (43.8) Interest expense and amortization of debt discounts and fees (41.6) — — — (41.6) Stock-based compensation (10.0) 3.0 — — (7.0) Loss on disposal or impairment of assets 1.3 — (3.3) — (2.0) Income from continuing operations before income tax expense 104.7 3.0 (3.3) — 104.4 Provision for income tax expense (39.7) (1.1) 6.1 (0.6) (35.3) Income from continuing operations attributable to HealthSouth $ 65.0 $ 1.9 $ 2.8 $ (0.6) $ 69.1 Add: Interest on convertible debt, net of tax 2.5 2.5 Numerator for diluted earnings per share $ 67.5 $ 71.6 Diluted earnings per share from continuing operations* $ 0.68 $ 0.02 $ 0.03 $ (0.01) $ 0.72 Diluted shares used in calculation 99.2 Adjusted EPS(5) - Q4 2016 * Adjusted EPS may not sum across due to rounding. Reconciliations to GAAP provided on pages 35-43; Refer to pages 44-45 for end notes.

41 For the Three Months Ended December 31, 2015 Adjustments As Reported Gov’t, Class Action, & Related Settlements Pro. Fees - Acct., Tax, & Legal Income Tax Valuation & Other Adj. Transaction Costs Loss on Early Exting. of Debt As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 191.5 $ — $ — $ — $ — $ — $ 191.5 Depreciation and amortization (41.4) — — — — — (41.4) Government, class action, and related settlements 0.5 (0.5) — — — — — Professional fees - accounting, tax, and legal (0.3) — 0.3 — — — — Loss on early extinguishment of debt (2.4) — — — — 2.4 — Interest expense and amortization of debt discounts and fees (44.6) — — — — — (44.6) Stock-based compensation (4.4) — — — — — (4.4) Loss on disposal or impairment of assets (2.4) — — — — — (2.4) Transaction costs (6.7) — — — 6.7 — — Income from continuing operations before income tax expense 89.8 (0.5) 0.3 — 6.7 2.4 98.7 Provision for income tax expense (43.5) 0.2 (0.1) 4.7 (2.1) (1.0) (41.8) Income from continuing operations attributable to HealthSouth $ 46.3 $ (0.3) $ 0.2 $ 4.7 $ 4.6 $ 1.4 $ 56.9 Add: Interest on convertible debt, net of tax 2.4 2.4 Numerator for diluted earnings per share $ 48.7 $ 59.3 Diluted earnings per share from continuing operations* $ 0.48 $ — $ — $ 0.05 $ 0.05 $ 0.01 $ 0.59 Diluted shares used in calculation 100.6 Adjusted EPS(5) - Q4 2015 * Adjusted EPS may not sum across due to rounding. Reconciliations to GAAP provided on pages 35-43; Refer to pages 44-45 for end notes.

42 For the Year Ended December 31, 2016 Adjustments As Reported Pro. Fees - Acct., Tax, & Legal Mark-to- Market Adjustment for Stock Appreciation Rights Loss on Early Exting. of Debt Sale of Pediatric Home Health Assets and Hospital Income Tax Valuation and Other Adjustments As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 793.6 $ — $ — $ — $ — $ — $ 793.6 Depreciation and amortization (172.6) — — — — — (172.6) Professional fees - accounting, tax, and legal (1.9) 1.9 — — — — — Loss on early extinguishment of debt (7.4) — — 7.4 — — — Interest expense and amortization of debt discounts and fees (172.1) — — — — — (172.1) Stock-based compensation (27.4) — 1.6 — — — (25.8) Loss on disposal or impairment of assets (0.7) — — — (4.2) — (4.9) Income from continuing operations before income tax expense 411.5 1.9 1.6 7.4 (4.2) — 418.2 Provision for income tax expense (163.9) (0.8) (0.6) (3.0) 6.5 (0.6) (162.4) Income from continuing operations attributable to HealthSouth $ 247.6 $ 1.1 $ 1.0 $ 4.4 $ 2.3 $ (0.6) $ 255.8 Add: Interest on convertible debt, net of tax 9.7 9.7 Numerator for diluted earnings per share $ 257.3 $ 265.5 Diluted earnings per share from continuing operations* $ 2.59 $ 0.01 $ 0.01 $ 0.04 $ 0.02 $ (0.01) $ 2.67 Diluted shares used in calculation 99.5 Adjusted EPS(5) - YTD 2016 * Adjusted EPS may not sum across due to rounding. Reconciliations to GAAP provided on pages 35-43; Refer to pages 44-45 for end notes.

43 For the Year Ended December 31, 2015 As Reported Gov’t, Class Action, & Related Settlements Pro. Fees - Acct., Tax, & Legal Income Tax Valuation & Other Adj. Mark-to- Market Adjustment for Stock Appreciation Rights Transaction Costs Loss on Early Exting. of Debt As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 682.5 $ — $ — $ — $ — $ — $ — $ 682.5 Depreciation and amortization (139.7) — — — — — — (139.7) Government, class action, and related settlements (7.5) 7.5 — — — — — — Professional fees - accounting, tax, and legal (3.0) — 3.0 — — — — — Loss on early extinguishment of debt (22.4) — — — — — 22.4 — Interest expense and amortization of debt discounts and fees (142.9) — — — — — — (142.9) Stock-based compensation (26.2) — — — 1.2 — — (25.0) Loss on disposal or impairment of assets (2.6) — — — — — — (2.6) Transaction costs (12.3) — — — — 12.3 — — Income from continuing operations before income tax expense 325.9 7.5 3.0 — 1.2 12.3 22.4 372.3 Provision for income tax expense (141.9) (3.0) (1.2) 4.7 (0.5) (4.1) (9.0) (155.0) Income from continuing operations attributable to HealthSouth $ 184.0 $ 4.5 $ 1.8 $ 4.7 $ 0.7 $ 8.2 $ 13.4 $ 217.3 Add: Interest on convertible debt, net of tax 9.4 9.4 Numerator for diluted earnings per share $ 193.4 $ 226.7 Diluted earnings per share from continuing operations* $ 1.92 $ 0.04 $ 0.02 $ 0.05 $ 0.01 $ 0.08 $ 0.13 $ 2.24 Diluted shares used in calculation 101.0 Adjusted EPS(5) - YTD 2015 * Adjusted EPS may not sum across due to rounding. Reconciliations to GAAP provided on pages 35-43; Refer to pages 44-45 for end notes.

44 End Notes (1) Current income tax expense was $17.4 million and $4.4 million for Q4 2016 and Q4 2015, respectively. Current income tax expense was $31.0 million and $14.8 million for the year ended December 31, 2016 and 2015, respectively. (2) The interest and amortization related to the convertible senior subordinated notes must be added to income from continuing operations when calculating diluted earnings per share because the debt is assumed to have been converted and the applicable shares are included in the diluted share count. (3) The increase in the Company’s income tax valuation allowance in 2015 related primarily to changes to its state apportionment percentages resulting from its acquisitions of Encompass, Reliant, and CareSouth as well as changes to its forecast of earnings in each jurisdiction. (4) In connection with the Encompass acquisition, the Company granted stock appreciation rights based on the common stock of HealthSouth Home Health Holdings, Inc. to certain members of Encompass management. The fair value of Holdings’ common stock is determined using the product of the trailing 12-month specified performance measure for Holdings and a specified median market EBITDA multiple based on a basket of public home health companies. The fair value of these stock appreciation rights will vary from period to period based on Encompass’ performance and the change in the multiple of the basket of public home health companies. (5) HealthSouth is providing adjusted earnings per share from continuing operations attributable to HealthSouth (“adjusted earnings per share”), which is a non-GAAP measure. The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing performance to prior periods given that it excludes the impact of government, class action, and related settlements, professional fees - accounting, tax, and legal, mark-to-market adjustments for stock appreciation rights, gains or losses related to hedging instruments, loss on early extinguishment of debt, adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims), items related to corporate and facility restructurings, and certain other items deemed to be non-indicative of ongoing operations. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company's ongoing operations. Accordingly, they can complicate comparisons of the Company's results of operations across periods and comparisons of the Company's results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies.* (6) Definition of adjusted free cash flow, which is a non-GAAP measure, is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, dividends paid on preferred stock, distributions to noncontrolling interests, and certain other items deemed to be non-indicative of ongoing operations. Common stock dividends are not included in the calculation of adjusted free cash flow. (7) Adjusted EBITDA is a non-GAAP financial measure. The Company’s leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future HealthSouth may incur expenses similar to the adjustments set forth. (8) In March 2006, the Company completed the sale 400,000 shares of its 6.5% Series A Convertible Perpetual Preferred Stock. In Q4 2013, the Company exchanged $320 million of newly issued 2.0% Convertible Senior Subordinated Notes due 2043 for 257,110 shares of its outstanding preferred stock. In April 2015, the Company exercised its rights to force conversion of all outstanding shares of its preferred stock. On the conversion date, each outstanding share of preferred stock was converted into 33.9905 shares of common stock, resulting in the issuance of 3,271,415 shares of common stock. (9) The contractual debt repayment obligations in 2017 includes ~$15 million of capital lease payments and ~$1 million of other notes payable. (10) On July 16, 2015, the board of directors approved a $0.02 per share, or 9.5%, increase to the quarterly cash dividend on the Company’s common stock, bringing the quarterly cash dividend to $0.23 per common share. On July 21, 2016, the board of directors approved a $0.01 per share, or 4.3%, increase to the quarterly cash dividend on the Company’s common stock, bringing the quarterly cash dividend to $0.24 per common share. (11) The Medicare Access and CHIP Reauthorization Act of 2015 mandated a market basket update of +1.0% in 2018 for post-acute providers including rehabilitation hospitals as well as home health and hospice agencies. * Reconciliations to GAAP provided on pages 35-43.

45 End Notes, con’t. (12) The Company estimates the expected impact of each rule utilizing, among other things, the acuity of its patients over the 8-month (home health segment) to 12- month (inpatient rehabilitation segment) period prior to each rule’s release and incorporates other adjustments included in each rule. These estimates are prior to the impact of sequestration. (13) HealthSouth acquired an additional 30% equity interest in Fairlawn Rehabilitation Hospital in Worcester, MA from its joint venture partner. This transaction increased HealthSouth’s ownership interest from 50% to 80% and resulted in a change in accounting for this hospital from the equity method to a consolidated entity effective June 1, 2014. (14) Data provided by Uniform Data System for Medical Rehabilitation, a division of UB Foundation Activities, Inc., a data gathering and analysis organization for the rehabilitation industry; represents ~70% of industry, including HealthSouth sites (15) Represents discharges from 122 consolidated hospitals in Q4 2016; 121 consolidated hospitals in Q3 2016; 120 consolidated hospitals in Q2 2016; 121 consolidated hospitals in Q1 2016; 120 consolidated hospitals in Q4 2015; 108 consolidated hospitals in Q3 2015 and Q2 2015; and 106 consolidated hospitals in Q1 2015 (16) Excludes approximately 420 full-time equivalents in the 2016 periods and approximately 400 full-time equivalents in the 2015 periods presented who are considered part of corporate overhead with their salaries and benefits included in general and administrative expenses in the Company’s consolidated statements of operations. Full-time equivalents included in the table represent HealthSouth employees who participate in or support the operations of the Company’s hospitals. (17) Employees per occupied bed, or “EPOB,” is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company’s occupancy percentage. (18) Represents home health admissions from 186 consolidated locations in Q4 2016; 188 consolidated locations in Q3 2016; 187 consolidated locations in Q2 2016; 184 consolidated locations in Q1 2016 and Q4 2015; 141 consolidated locations in Q3 2015; 139 consolidated locations in Q2 2015; and 143 consolidated locations in Q1 2015 (19) Represents hospice admissions from 35 locations in Q4 2016; 33 locations in Q3 2016; 29 locations in Q2 2016; 27 locations in Q1 2016 and Q4 2015; 23 locations in Q3 2015; and 21 locations in Q2 2015 and Q1 2015. (20) In November 2013, the Company closed separate, privately negotiated exchanges in which it issued $320 million of 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of its 6.5% Series A Convertible Perpetual Preferred Stock. The Company recorded ~$249 million as debt and ~$71 million as equity. The convertible notes are convertible, at the option of the holders, at any time on or prior to the close of business on the business day immediately preceding December 1, 2043 into shares of the Company’s common stock and is subject to customary antidilution adjustments. The Company has the right to redeem the convertible notes before December 1, 2018 if the volume weighted-average price of the Company’s common stock is at least 120% of the conversion price ($44.59) of the convertible notes for a specified period. On or after December 1, 2018, the Company may, at its option, redeem all or any part of the convertible notes. In either case, the redemption price will be equal to 100% of the principal amount of the convertible notes to be redeemed, plus accrued and unpaid interest. (21) The agreement to settle the Company’s class action securities litigation received final court approval in January 2007. The 5.0 million shares of common stock and warrants to purchase ~8.2 million shares of common stock at a strike price of $41.40 (expired January 17, 2017) related to this settlement were issued on September 30, 2009. The 5.0 million common shares are included in the basic outstanding shares. The warrants were not included in the diluted share count prior to 2015 because the strike price had historically been above the market price. In Q4 2016, full-year 2016, Q4 2015, full-year 2014, and full-year 2013, zero shares related to the warrants were included in the diluted share count due to antidilution based on the stock price. In full-year 2015, 80,814 shares related to the warrants were included in the diluted share count using the treasury stock method. See also page 31.